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Abstract
In silico modelling approaches are useful since they can minimise experimental
costs and once set up can be used to replace animal testing for drugs. As such
modelling techniques need to be developed to reduce dependence on animals for
validation of pharmacological efficacy. The work within this thesis shows that
computational methods can be used to model biological and medical problems
effectively.
The main aim of this thesis was to investigate Cytochrome P450 enzymes and
their effect on drug metabolism through the use of the Hepatic Reductase Null
(HRN) mouse. This was done through using a number of computational models
and compared with drug data provided by CXR Biosciences.
These models ranged from solely ODE (for comparison to experimental data) to
multiscale cellular automata and spatial models when analysing the dynamics on
the tumour and cellular level. Once these models were developed the parametric
sensitivity was derived in order to see whether there were any needless parameters
so that the models were streamlined and to test the model‘s robustness against
error.
The novel three-compartment model was developed in order to explain dynamics
within the Hepatic Reductase Null mouse was able to explain much of the be-
haviour in the supplied data. As well as this it was discovered that the transgenic
mouse showed reduced speed in metabolism for many of the drugs analysed which
meant that different models were sometimes necessary.
xiv
The cellular automaton program presented is applicable to other areas other than
the one stated in Chapter 5. For example any area that deals with interactions
between tissue media and drugs as in toxicology and drug studies. The cell cycle
inside the code deals with tumour cells but this code can be re-parameterised to
concentrate on other types of cell including normal cells, hepatic tissue etc.
The inclusion of spatial effects to the deterministic models like the Cytochrome
P450 cycle allows for greater realism in predictions of drug passage through the
body or across certain tissue media. Due to this it is useful to include both de-
terministic and spatial modelling with a multiscale approach in models for drug
metabolism.
xv
Chapter 1
Cytochrome P450 Enzymes
1.1 Motivation and Aims
All Cytochrome P450 enzymes are responsible for more than 90% of metabolism
for all drugs (Parikh et al., 1997), which means that drug-drug interactions are
very important to model prior to administration of therapy. Greater research is
needed into the functionality of Cytochrome P450 in order to be able to predict
the outcome with relation to the compound.
The most recent area of research related to Cytochrome P450 is that of cancer
therapeutics. Their use in this area is one of metabolism, activation or inacti-
vation. This is particularly important for prodrugs like Cyclophosphamide and
Ifosfamide (Yu et al., 1999). These processes happen mostly within the hepatic
system where the enzymes are most abundant. These enzymes are also found in
and tumour tissue which can have positive or negative effects on anticancer drugs
due to these activities (McFadyen et al., 2004). This could mean that the tumour
tissue is left unaffected by the drug due to being inactivated by local CYP sources
and as such ineffective.
It is due to these reasons that aim of this thesis was to concentrate on the Cy-
tochrome P450 enzyme family and their effect on drug metabolism.
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Initially this was through the use of the Hepatic Reductase Null (HRN) mice
in comparison to their wild type counterparts shown in Chapter 3. This was
done through using a number of different compartmental models and compared
with drug data provided by CXR Biosciences. The main focus of this modelling
was whether there were metabolic differences that were produced as a side ef-
fect of genetic mutation in the transgenic mouse. A three-compartment model
was developed through adding time dependent excretion and a compartment that
represented the fat cells in the liver that may change the dynamics of lipophilic
drugs.
After this solely deterministic approach a cellular automaton was then devel-
oped in Chapter 5 to analyse how the Cytochrome P450 enzymes affect drug
metabolism in general. The results were not compared to the data used in Chap-
ter 3 as the aim was to get an indication of how the CYP enzymes would affect
drug dynamics in a tumour.
In Chapter 6 a COMSOL simulation was performed on a singular cell to see
whether spatial effects such as the fact that P450 enzymes are mostly found in
Smooth Endoplasmic Reticulum on the cellular level would affect the drug dy-
namics.
The rest of this chapter will be dedicated to the location and functionality of
Cytochrome P450 enzymes. In the following chapter an introduction to Drug
modelling can be found. These two chapters should provide a good understand-
ing for the modelling found within this thesis.
1.2 Introduction
Cytochrome P450 is a large class of enzymes, which constitute a superfamily of
hemoproteins. The name Cytochrome P450 was first used in 1961 because of the
pigment (P) having a spectral peak at 450nm when bound to carbon monoxide
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(Nebert and Russell, 2002). At this point in time it was thought that there was
only one enzyme but since then there have been numerous discoveries of related
enzymes.
These proteins are categorised into families dependent on amino-acid correlation.
There are 18 families and 42 subfamilies of CYP (Cytochrome P450) enzymes
(Pirmohamed and Park, 2003). Families are defined as having more than 40%
identity in genetic structure whereas subfamilies have more than 55% (de Groot,
2006). Out of the 18 families CYP1, CYP2, CYP3 and to a lesser extent CYP4
deal with drug metabolism.
There are many factors that affect the activity and functionality of Cytochrome
P450 these are: age, gender, drug, smoking, alcohol, disease and polymorphisms
(Cheng et al., 2009). Hepatic drug metabolism decreases with age in animals
(Sotaniemi et al., 1997) and in humans age comes with diminished liver mass,
blood flow and hepatic metabolising enzyme activity (Scripture et al., 2005). Al-
though gender is thought to have an effect on P450 activity in the liver it has not
yet been proven (George et al., 1995).
Excessive alcohol consumption can cause liver disease and cirrhosis, which in turn
causes impaired liver function, since, for example, liver disease causes drug clear-
ance to be reduced and cirrhosis is characterised by the replacement of normal
liver tissue with scar tissue. This sometimes leads to cytotoxic chemotherapy
not being offered due to the large probability of adverse drug reaction (Scripture
et al., 2005). Hypoxemia can also cause diminished CYP activity due to its de-
pendency on oxygenated conditions. This is a serious complication to a number
of common diseases (Ju¨rgens et al., 2002).
A polymorphism is a genetic variation that is present in a population (Martin
and Hine, 2004). These can cause adverse drug reactions due to increased or de-
creased in the CYP enzyme activity with reference to any particular drug (Evans
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and Relling, 1999) and therefore plays a large role in interpatient variability
(Cheng et al., 2009). If the enzyme activity is decreased this could cause a longer
half-life within the body before it is cleared this is known as a poor metabolism
phenotype. Different alleles of the 2C9, 2C19, 2D6, 3A4, 3A5, 2A6 and 2B6 drug
metabolising genes can result in failures in treatment, which can lead to toxic
effects, or even death in rare cases (Meyer, 2000; Phillips et al., 2001). A list
of polymorphic (shows polymorphisms) genes and the effect on certain medica-
tions were collated by Evans and Relling (1999). This paper also illuminates just
how powerful a change in Cytochrome P450 enzyme panel can affect therapeutic
efficacy.
1.2.1 Location
These enzymes are found in all living things with the exception of E. coli (Munro
and Lindsay, 1996)that can be used to generate Cytochrome P450 enzymes for
experimental procedures (Guengerich et al., 1997).
Cytochrome P450 enzymes are found all over the body but they are primarily
located in the liver (McFadyen et al., 2004). Low levels are found in the brain,
lungs, intestine and kidneys (Venkatakrishnan et al., 2001; Mace´ et al., 1998).
On the cellular level this enzymatic system is located within the Smooth Endo-
plasmic Reticulum (SER) (Tsui, 2003). Human Cytochrome P450 enzyme levels
are difficult to obtain due to difficulty in obtaining healthy liver tissue (Kinirons
and O’Mahony, 2004) from humans. An expression study on 1A2, 2A6, 2B6, 2C,
2D6, 2E1 and 3A4 showed that (Mace´ et al., 1998):
Peripheral lung tissue Bronchial Mucosa Both
1A2 and 3A4 2C9 2C8, 2A6, 2E1 and 2B6
Table 1.1: Study results for location of Cytochrome P450 enzymes.
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These chemicals not only occur through the normal function of systems through-
out the body but also are associated with tumours. McFadyen et al. (2001) while
looking at anticancer drug resistance found a link between CYP1B1 overexpres-
sion and cancer. The work of Tanaka et al. (2004) showed that the analysis of
tumour tissue in cancer patients could help to predict the efficacy of anti-cancer
drugs with respect to metabolism including Cytochrome P450 enzymatic reac-
tions.
Liver
This organ is very important in drug metabolism and is the largest gland in the
human body. As you can see from the figure below it is boomerang shaped and
has a large vein passing through it. This allows for the blood flow to have quicker
diffusion through the system since there is a large surface area connecting the
tissue to the vein.
With reference to drug metabolism the drug has two chances to be cleared by the
liver due to first-pass metabolism. This is where the blood flow can immediately
go to the liver before the gut. Then when it escapes the hepatic system it can
proceed to the gut and then return to the liver once more. This allows for drugs
to be cleared from the body much quicker.
Figure 1.1: Schematic diagram of the liver (Online., 2011a).
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The liver is one of a few organs in the body that is regenerative such that if
70% of the liver was removed it could become the whole organ again (Khan and
Mudan, 2007). This is why liver transplantation usually takes the left lobe (right
in the above figure) and leaves the donor with only the right lobe.
The Cytochrome P450 enzymes are found in the different liver cells for example
hepatocytes and Kupffer cells (Lu and Cederbaum, 2008).
Figure 1.2: Schematic diagram of the liver (Online., 2011b).
This figure shows the location of these two types of cells. As they are in
different areas of the liver there is a spatial dimension to drug metabolism within
the liver.
1.3 Main CYP enzymes
Out of all the Cytochrome P450 enzymes that exist within the human body there
are nine strains that are responsible for ninety percent of the metabolic activity
(Cozza et al., 2003). These are (six major) 1A2, 3A4, 2C9, 2C19, 2D6, 2E1,
(three minor) 2A6, 2B6 and 2C8.
In what follows is an explanation of specific functional details for each enzyme
and known interactions with drugs. These interactions are either metabolic, in-
hibitory or the drug induces production of the enzyme. Some of the drugs outlined
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are studied in Chapter 3 with compartment models but most are just shown to
illustrate the wide range of substrates Cytochrome P450 interact with.
1.3.1 CYP1A2 enzyme
This enzyme is the predominant CYP1A form in all species (Caccia et al., 2009)
that is exclusively expressed in the liver (Cozza et al., 2003) and it represents
10-15% of the organs P450 activity. The associated gene is conserved in mam-
mals, birds and fish but not in lower eukaryotes (Schenkman and Greim, 1993).
This gene is polymorphic (Tredger and Stoll, 2002) but no major phenotypes that
cause adverse drug reactions have been reported currently.
It only plays a minor role in drug metabolism since it is merely responsible for
5% of therapeutically used drugs (Wolf and Smith, 1999).
Metabolism Inhibition Induced
Caffeine Fluvoxamine Omeprazole
Tamoxifen Ciprofloxacin
Table 1.2: Drugs that interact with CYP1A2 (Scripture et al., 2005; Cozza et al.,
2003; Tredger and Stoll, 2002).
Since this Cytochrome P450 enzyme metabolises caffeine this drug is used as
a probe for the level of CYP1A2 activity within the patient (Park et al., 1996).
This enzyme‘s activity has been reported to be larger in males than in females
(Caccia et al., 2009). As well as this women suffer from caffeine toxicity due to
the activity of 1A2, which is not the case in males (Clewell et al., 2002).
1.3.2 CYP3A4 enzyme
CYP3A4 is the major P450 isoform in adults from the 3A family (Ingelman-
Sundberg, 2001). Unlike the previous enzyme this strain is active in the liver,
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gastro-intestinal tract (Holmquist, 2009) and the small intestine (Cozza et al.,
2003) though it is considered to be primarily hepatic (Tredger and Stoll, 2002)
and is the most abundant P450 in the liver. Although this enzyme is predominant
in adult livers it is undetectable in babies (Plant, 2007) and this is the reason
why blood transfusions to this age group have to be monitored for drugs. The
presence of the enzyme in the small intestine although varied (Kato, 2008) causes
lower bioavailability of some substrates due to first pass metabolism.
Similarly to 1A2, CYP3A4 is polymorphic (Tredger and Stoll, 2002). Various
polymorphisms have been reported most are rare and of unknown function (Pir-
mohamed and Park, 2003). The fact that the function of these polymorphisms
is unpredictable is of particular concern for the metabolism of anti-cancer agents
(Rodriguez-Antona and Ingelman-Sundberg, 2006). This is because if the poly-
morphism results in a poor metabolism phenotype this can result in reduced
clearance of cyclophosphamide and thus poorer clinical response (Ekhart et al.,
2009).
CYP3A4 is responsible for metabolism of approximately 50% of drugs (Tang and
Stearns, 2001) and is the major xenobiotic metabolising enzyme in humans. This
enzyme has a wide range of compounds that it metabolises regardless of shape,
size (Beresford et al., 2002) and lipophilicity (Lewis, 2000). The work of Zhou
et al. (2005) showed how CYP3A4‘s low substrate specificity (interacts with many
compounds) makes the enzyme susceptible to inhibition. This inhibition can oc-
cur to the enzyme through reversible and irreversible formation of complexes that
inactivate the enzyme‘s functionality. Due to the large number of drugs that this
enzyme interacts with if a patient is prescribed multiple drugs they may suffer ad-
verse drug reactions (Marechal et al., 2006). As such overcoming the metabolism
of the drug can be achieved by two means: lipophilicity reduction and function-
ality removal.
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Metabolism Inhibition
Midazolam Grapefruit juice
Tamoxifen Erythromycin
Docetaxel
Omeprazole
Table 1.3: Drugs that interact with CYP3A4 (Smith et al., 2001; Hurria et al., 2006;
Lewis, 2000; Miners, 2002).
This enzyme’s activity can be modelled using the Erythromycin breath test(Hurria
et al., 2006).
1.3.3 CYP2C9 enzyme
This strain is found in many tissues but most of its drug metabolism activity
occurs in the liver (Cozza et al., 2003). It accounts for 18% of the P450 content
in the liver and this is why it is reported as primarily hepatic (Tredger and Stoll,
2002). This enzyme dominates over 2C19 (Venkatakrishnan et al., 2001) when
they compete for substrates.
This enzyme also shows polymorphisms (Venkatakrishnan et al., 2001) that can
complicate treatment through the presence of poor/rapid metabolism phenotypes
(Rodriguez-Antona and Ingelman-Sundberg, 2006).
Metabolism Inhibition Induced
Diclofenac Sulfinpyrazone Barbiturates
Paclitaxel Miconazole Carbamazepine
Tamoxifen Fluconazole Rifampin
Table 1.4: Drugs that interact with CYP2C9 (Scripture et al., 2005; Venkatakrishnan
et al., 2001; Cozza et al., 2003; Tredger and Stoll, 2002).
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1.3.4 CYP2C19 enzyme
As with CYP2C9, this strain is found in many tissues and along with CYP2C9,
is responsible for 20% of the hepatic P450 activity (Cozza et al., 2003). Out of
all the factors that affect P450 activity this enzyme is affected by an age-related
decrease (Scripture et al., 2005).
Polymorphisms have been recorded that are associated with deficient, reduced,
normal or increased enzyme activity (Belle and Singh, 2008). These phenotypes
include a poor metaboliser formulation that occurs in less than 5% of Caucasians
and 12-20% of Asian populations (Venkatakrishnan et al., 2001).
Metabolism Inhibition
Omeprazole Fluvoxamine, Omeprazole
Tamoxifen Fluconazole, Ticlopidine
Table 1.5: Drugs that interact with CYP2C19 (Scripture et al., 2005; Venkatakrishnan
et al., 2001; Cozza et al., 2003; Tredger and Stoll, 2002).
For poor metabolisers Omeprazole concentration is five-fold higher and rapid
metabolisers have 40% lower concentration, which can cause therapeutic failure
(Belle and Singh, 2008) due to the drug levels not being high enough to be
effective. Gender differences in the enzyme have been recorded in the literature
but no consensus on whether males or females have greater activity has been
reached (Clewell et al., 2002).
1.3.5 CYP2D6 enzyme
CYP2D6 is the only member of the CYP2D family, which functions in humans
(Caccia et al., 2009). This enzyme is reported to be primarily hepatic (Tredger
and Stoll, 2002) but is also found in brain, prostate, bone marrow and heart tis-
sue (Cozza et al., 2003). 2D6 accounts for 1.5% of the P450 liver content (Cozza
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et al., 2003).
As with the Cytochrome P450 enzymes described earlier this strain is also poly-
morphic. There are at least 75 genetic polymorphisms (Belle and Singh, 2008)
ranging from deficient to ultra rapid. Approximately 8% of European and North
American Caucasians have two copies of mutant CYP2D6 alleles causing the en-
zyme to be absent (Schenkman and Greim, 1993). This genetic defect is called
debrisoquine polymorphism.
This enzyme has become a key metabolising enzyme in drug development, re-
sponsible for an estimated 25% of all drugs (Belle and Singh, 2008). It is so
important to the extent that if a drug shows more than 40% of its clearance is
dependent on CYP2D6 (Pirmohamed and Park, 2003), the development is halted.
Metabolism Inhibition
Dextromethorphan Quinidine, Fluoxetine
Tamoxifen Paroxetine, Perplenazine
Codeine Terbinafine, Ticlopidine
Table 1.6: Drugs that interact with CYP2D6 (Cozza et al., 2003; Tredger and Stoll,
2002; Venkatakrishnan et al., 2001; Rang, 2003; Belle and Singh, 2008).
For this enzyme Dextromethorphan is used as a probe drug to check activity
level (Park et al., 1996).
1.3.6 CYP2E1 enzyme
This enzyme is located almost exclusively in the liver and represents 5-7% of
all hepatic Cytochrome activity (Venkatakrishnan et al., 2001). 2E1 shows re-
sistance to the toxic effects of benzene so is indicative of this enzymes role in
xenobiotics metabolism (Gonzalez and Kimura, 2003). This strain was the only
member of the CYP2E family in humans since CYP2E2 is only expressed in rab-
bits (Schenkman and Greim, 1993).
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CYP2E1 has also been reported as polymorphic (Tredger and Stoll, 2002) but
no actual polymorphisms have been found (Rodriguez-Antona and Ingelman-
Sundberg, 2006).
Metabolism Inhibition Induced
Caffeine, Tamoxifen Disulfiram Ethanol, Isoniazid
Ethanol, Paracetamol Diethylcarbamate Nicotine
Table 1.7: Drugs that interact with CYP2E1 (Scripture et al., 2005; Tredger and Stoll,
2002; Rang, 2003; Venkatakrishnan et al., 2001; Lu and Cederbaum, 2008; Dutheil
et al., 2008; Lewis, 2000).
Many substrates associated with CYP2E1 induce their own metabolism (Lu
and Cederbaum, 2008).
1.3.7 CYP2A6 enzyme
This enzyme is indigenous to hepatic and extrahepatic tissues (Tredger and Stoll,
2002) and comprises 4% of liver P450 content (Venkatakrishnan et al., 2001).
CYP2A6, as with the other Cytochrome P450 enzymes, is polymorphic in humans
and can lead to a reduced capacity for metabolising nicotine and a reduced risk
to tobacco dependence. Experiments are underway to treat smoking dependence
(Venkatakrishnan et al., 2001) in a hope to cure it.
As well as this, the polymorphisms have been linked with tobacco-induced can-
cers. This is due to its activity in the metabolism of nicotine and tobacco pre-
carcinogens (Rodriguez-Antona et al., 2010).
1.3.8 CYP2B6 enzyme
Out of all the P450 isoforms in the hepatic system this one has low abundance
(Venkatakrishnan et al., 2001) and represents less than 1% of the activity (Cozza
et al., 2003). However although it is primarily hepatic (Tredger and Stoll, 2002)
12
it is also detected in extrahepatic tissues including the intestines, kidney, lung,
skin and the brain (Miksys et al., 2003; Yengi et al., 2003). This strain shows
large interindividual variance (Venkatakrishnan et al., 2001; Rodriguez-Antona
and Ingelman-Sundberg, 2006) that was shown to be more than a hundred fold
in a study of the activity in liver microsomes.
Metabolism
Midazolam and Tamoxifen
Table 1.8: Drugs that interact with CYP2B6 (Tredger and Stoll, 2002).
1.3.9 CYP2C8 enzyme
This enzyme has only a minor role in drug metabolism (Cozza et al., 2003). Poly-
morphisms for this enzyme exist but do not seem to be functionally important
(Kirchheiner and Seeringer, 2007). However, it does affect Paclitaxel clearance
(Spratlin and Sawyer, 2007).
Metabolism Inhibition
Paclitaxel and Ibuprofen Quercetin
Table 1.9: Drugs that interact with CYP2C8 (Tredger and Stoll, 2002; Venkatakrish-
nan et al., 2001; Mart´ınez et al., 2005).
In a study by Mart´ınez et al. (2005) they showed that 30% of the population
carry an alternative allele CYP2C8 that interferes with ibuprofen metabolism.
1.4 Functionality
For Cytochrome P450 enzymes to function, both a substrate and a cofactor, for
example NAD(P)H, are necessary. These three groups form a cyclical relationship
in order to keep the enzyme working. This is shown by the fact that Cytochrome
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P450 expression increases when there is more substrate to use and vice-versa.
P450 systems vary greatly from species to species and this difference is mainly
seen in the identity of the cofactors. In fact these changes show a prokary-
otic/eukaryotic divide. This division is shown by the fact that eukaryotic systems
have Cytochrome P450 reductase (CPR), FAD (flavin adenine dinucleotide) and
FMN (Flavin mononucleotide) cofactors and prokaryotic systems do not. (Parikh
et al., 1997; McLean et al., 2005). These eukaryotic systems are also responsible
for the reduction of foreign compounds like anti-cancer drugs (Do¨hr et al., 2001).
Figure 1.3: Schematic diagram of the Cytochrome P450 cycle.
The Cytochrome P450 cycle shown in figure 1.3 is based on a scheme discussed
in a paper by Guengerich (2001). It is a simplified cycle specifically tailored for
CYP1A2 enzymes. Although these enzymes only represent a small proportion of
hepatic CYP activity they are conserved across higher eukaryotic species. Due to
this it should be possible to relate this cycle to the other strains. The cycle starts
with the unbound enzyme, E, which represents a P450 enzyme with an Iron (III)
core. This then comes into contact with some substrate, S, which in this chapter
is the drug variable. These two then bind together to form an enzyme-drug com-
plex, ES. This complex is formed in equilibrium outlined in the following equation:
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E + S ⇀↽ ES (1.1)
This reaction is governed by two rate constants k−1 and k1. Since this complex
is in equilibrium it is still unstable and until the iron core is reduced to Iron (II)
using an electron from a cofactor e.g. CPR, this is then called FS in the cycle.
This part of the cycle is controlled by a rate constant, k2, in the equation:
ES → FS (1.2)
This complex then binds with oxygen to form FSO2 as outlined by the equation:
FS +O2 ⇀↽ FSO2 (1.3)
This is another equilibrium with a forward and backwards reaction governed by
the rate constants k3 and k−3 respectively. This complex then forms GSO2 with
the addition of a H+ and an electron from a cofactor e.g. CPR or Cytochrome
b5 reductase. This is shown in the equation governed by the rate constant k4:
FSO2→ GSO2 (1.4)
This complex also breaks down as shown by the equation:
GSO2→ E + S +H2O2. (1.5)
This is associated with the rate constant k8. However this reaction does not com-
pletely reduce GSO2 levels and some is converted to HSO and then a second H+
cleaving water from the complex by the equations:
GSO2→ HSO (1.6)
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HSO → E + S +H2O. (1.7)
These equations are governed by the constants k5 and k9 respectively. HSO is
then changed to an enzyme-product complex, EP, which is unstable:
HSO → EP (1.8)
The rate constant for this is k6 and then the EP complex breaks down into en-
zyme and oxidised drug or product, P. The equation for this with constants k7
and k−7 is:
EP ⇀↽ E + P (1.9)
The interactions between Cytochrome P450 and the substrate are not always
positive. Cytochrome P450 interacts with drugs to metabolise them into stable
or toxic metabolites (Pirmohamed and Park, 2003). This is why greater research
is needed into the functionality of Cytochrome P450 in order to be able to predict
the outcome with relation to the compound.
The dependence of Cytochrome P450 enzymes on the presence of CPR has been
reviewed in Omura (2010). Another cofactor that has been proposed since early
studies is Cytochrome b5, which has been shown to exert various influences on
P450 catalytic systems. It is unclear whether it is a physical association with
the particular Cytochrome P450 or electron transfer capability (Yamazaki et al.,
1996). The work of Finn et al. (2008) states that Cytochrome b5 affects CYP2C8,
2C9, 2C19, 2D6, 2E1 and 3A4 activity.
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1.5 Use of Cytochrome P450 Enzymes in Phar-
maceuticals
The use of Cytochrome P450 enzymes in drug development is in its early stages
and has not been fully utilised yet (Guengerich, 2002). Examples of this are in
the production of: chemicals that have anticarcinogenic properties like perillyl
alcohol (van Beilen et al., 2005) and antibiotics using microbial CYP‘s.
Not only can Cytochrome be used as a drug target and a metaboliser, it can also
help with drug synthesis. For example, Cytochrome P450 enzymes have been
isolated from yeast and used to catalyse the biosynthesis of Taxol (Paclitaxel),
an anticancer drug (Jennewein et al., 2005). A review of the use of Cytochrome
P450 monooxygenases as biocatalysts can be found in Winklerb et al. (2010).
This paper also classifies these enzyme systems as to their usefulness for certain
substrate reactions.
In recent research it has been theorised that these enzymes can also be used to
monitor drug levels in the body (Guengerich, 2002) and vice versa. For example
caffeine metabolites could monitor CYP2E1 levels (Schenkman and Greim, 1993)
and using this method can ensure that drug dose does not reach toxic levels The
work of Roy et al. (1999) showed that there were differences in Cytochrome P450
expression profiles when under the influence of drugs like cyclophosphamide and
ifosfamide.
Cytochrome P450 plays an important role in primary and secondary metabolism
and drug degradation (Urlacher and Eiben, 2006). CYP1-3 are responsible for
70-80% of phase I metabolism and participate largely in the metabolism of other
xenobiotics (Ingelman-Sundberg, 2004) including lipophilic chemicals (Lin and
Lu, 1998). Yang et al. (2006) showed that not all CYP subfamilies are involved
in the bioactivation of drugs. Only CYP1A, 2C, 2E and 3A subfamilies are
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involved whereas 2B and 2D play little to no part. This set of enzymes is known
to cooperate so that they can be responsible for the metabolism of all xenobiotics
(Beresford et al., 2002). The effect of drugs on CYP activity is thought to be due
to drug inhibition due to competition or non-competition within the liver causing
toxicity (Tang and Stearns, 2001).
1.6 Chemical interactions
The work of Holmquist (2009) showed that substances entering the body can act
in three ways - as a substrate, as an enzyme inhibitor or inducer. A substrate
can also induce/inhibit one or more CYP450 enzymes simultaneously.
This type of enzyme acts in number of ways due to the vast number of mem-
bers. The main ways it interacts with compounds in the body through the use
of substrates available are - oxidation, peroxidation, epoxidation, reduction and
hydroxylation (Maurer et al., 2005).
Not all drug oxidation exclusively involves the P450 system. For example, ethanol
is metabolised by alcohol dehydrogenase in addition to the CYP2E1 enzyme
(Rang, 2003).
These enzymes are very versatile with relation to the compounds they can in-
teract with e.g. drugs, pollutants and plant products. However the interactions
between Cytochrome P450 and the chemical are both positive and negative.
A positive example is that some mammalian CYP‘s such as 2E1 are able to
metabolise low molecular weight hydrocarbons (Rodriguez-Antona and Ingelman-
Sundberg, 2006) and haloalkanes. It is this ability that makes them useful in
bioremediation (Guengerich, 2002)They have been used to clear up oil spills and
landfill created chemicals.
Cytochrome P450 interacts with drugs to metabolise them into stable or toxic
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metabolites (Pirmohamed and Park, 2003) that can cause negative side effects.
1.7 Cancer
The most recent area of research related to Cytochrome P450 is that of cancer
therapeutics. Their use in this area is one of metabolism, activation or inactiva-
tion. When a precarcinogen enters the human body Cytochrome P450 is one of
the main enzymes responsible for mediation of its activation and detoxification
(Rodriguez-Antona and Ingelman-Sundberg, 2006). For anti-cancer drugs Cy-
tochrome P450 participates in the activation and inactivation of the compounds,
which is particularly important for prodrugs like Cyclophosphamide and Ifos-
famide (Yu et al., 1999). This process happens mostly within the hepatic system
where the enzymes are at their strongest in number. The presence of CYP around
tumour tissue can have positive or negative effects on anticancer drugs due to its
activation/inactivation protocols (McFadyen et al., 2004). This could mean that
the tumour tissue is left unaffected by the drug due to being inactivated by local
CYP sources.
For cancer therapy the liver system is very important but it should be under-
stood that there is also an extrahepatic tissue configuration that is also useful.
For example, CYP3A4 expression in breast tumour tissue can be used to predict
the response to Docetaxel (Miyoshi et al., 2002).
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Chapter 2
Drug Development and
Modelling
In the pharmacological industry the cost of creating new and innovative drugs
is an expensive area of research. This is due to the current methodology and
approach, which consist of drug creation and testing (Grass and Sinko, 2002)
without the knowledge of whether the functional groups will have the desired
effect on the human body. Due to this there is a growing need for computational
models investigating the metabolic and functional effect. These models should be
able to minimise the percentage of new drugs that get to clinical trials but fail to
make it to market due to poor bioavailability, toxicity and drug-drug interactions
(Ekins et al., 2000). As well as this it should be able to stop useful drugs being
rejected prematurely. This should reduce the development costs and therefore
the price of the drug in general when it reaches the market.
For orally administered drugs there exists a set of rules that was developed by
Lipinski in the late 1990‘s (Lipinski et al., 1997) and is known as “Lipinski’s rule
of drug likeness“ or the “rule of five“ (Zhang and Wilkinson, 2007). These rules
state that poor absorption/permeation are more likely when there are more than
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five hydrogen bonding donor sites (e.g. hydroxyl and amine functional groups at-
tached to the drug molecule) and more than ten acceptor sites (e.g. lone oxygen
or nitrogen). As well as this the rules suggest that a large molecular weight cou-
pled with a lipophilicity larger than five can cause poor metabolism. Compound
classes that are substrates for biological transporters are exceptions to the rules.
The rules are simple and easily applied in the screening of drugs but this can lead
to them being misused (Zhang and Wilkinson, 2007). The other issue with these
rules is that they exclude natural products and overemphasise oral bioavailabil-
ity. Zhang and Wilkinson (2007) argued that such a dependence on this could
mean that useful drugs may be disregarded due to poor oral bioavailability e.g.
Penicillin G. This drug has to be given through an intramuscular injection to
maximise efficacy. As such it should be used as a rule of thumb rather than a
strict testing procedure (Ekins et al., 2000).
2.1 ADME
Pharmacokinetics is a method of characterising the processes of drugs using the
headings of Absorption, Distribution, Metabolism and Elimination (ADME) (Ah-
mad, 2007). These four processes are able to separate the different mechanisms
of action for drugs so that models can be developed.
2.1.1 Absorption
Absorption of a drug is affected by both physiological and physiochemical prop-
erties. The physiological attributes are processes such as blood flow rate and first
pass metabolism in the human body that vary from species to species. Physic-
ochemical factors are the intrinsic properties of the drugs such as lipophilicity
(LogP) which do not vary across species (Lin, 1998).
21
This process does not affect metabolism of drugs that are given in an intravas-
cular method e.g. intravenously (i.v.). This is due to its immediate effect on the
biological system it was applied to (Ahmad, 2007).
2.1.2 Distribution
Distribution rate is what governs the speed by which the drug enters organs and
tissue and is controlled by blood flow perfusion rate. It is believed that only an
unbound drug can diffuse across the cellular membrane (Yang et al., 2006). Drug
distribution is usually thought of in terms of volume of distribution or Vd which
is defined as the ratio of drug in the body to that within the blood or plasma
(Lin, 1995).
The five main physiological properties that influence the extent to which a chem-
ical distributes through the human body are (Clewell et al., 2002) body com-
position, blood flow, plasma binding proteins, tissue-protein concentration and
fluid pH.
2.1.3 Metabolism
Metabolism as a process is similar across species from an evolutionary standpoint
due to a common ancestor, so only environmental adaptation can change this
method. For example, Cytochrome P450 (CYP) enzymes have all evolved from
the same ancestral gene to the present superfamily. As was shown in Chapter 1,
interspecies differences do exist for CYP enzymes and the inhibition and induc-
tion preferences also differ (Lin, 1998). Out of the four processes, metabolism is
the most difficult to model in silico since there are minimally a hundred (Beres-
ford et al., 2002) drug metabolising enzymes to account for (Dickins and van de
Waterbeemd, 2004).
22
Metabolism can be affected by drug-drug interactions since they can cause inhi-
bition or induction of drug metabolising enzymes like CYP. This information is
relevant to models since this can affect the course of the drug and the time it
takes to be metabolised in the body (Ahmad, 2007).
2.1.4 Elimination
Elimination processes are the methods by which drugs and their metabolites are
expelled from the human body. Examples of these are through urine and/or bile
but this depends on the pharmacological nature of the drugs. Hepatic and renal
processes control these and elimination can be modelled using saturable kinetics
such as Michaelis-Menten (Ahmad, 2007). Saturable kinetics is usually used with
enzymes since normally the substrate is dependent on the enzyme concentration
and as such this can be a limiting factor. As most of these processes seem to
vary across species it is understandable that extrapolation from one species to
another in order to predict a drug’s behaviour may not be the best approach due
to limited data (Ito et al., 1998). Due to this many scientists have been trying
to discover a way to scale the gap so that animal data can be used to predict
drug processes in the human body and this can be done under pharmacokinetic
principles (Lin, 1995).
2.2 QSAR Models
Another type of predictive model is the Quantitative Structure-Activity Relation-
ship (QSAR) or Quantitative Structure-Property Relationship (QSPR), which
provides insights into the molecular properties of drugs (Mager, 2006). For ex-
ample, physicochemical and molecular properties can be correlated with drug
concentrations to investigate pharmacological responses e.g. EC50. These studies
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have been used since the 1960s with physicochemical and biological data (van de
Waterbeemd and Gifford, 2003).
These models show what happens when certain properties such as lipophilicity
etc. change, and predict the binding affinity or the toxic potential of the struc-
ture. This approach has been used extensively and Lill (2007) shows how this
method can be used in multidimensional studies. The method has a high through-
put but only provides low level information (Cai et al., 2006) and tends to reject
molecules without giving guidance on the properties needing optimisation.
2.3 Compartmental and PBPK Models
Physiologically Based Pharmacokinetics (PBPK) are models made up of a series
of equations simulating the concentration of the parent compounds and metabo-
lites in various compartments (of the body) (Flynn et al., 1996).
Hunt et al. (2006) show that drug data is usually analysed by assuming that the
human body can be split into abstract compartments or in PBPK organs by com-
partments connected by a vascular system. This is useful since it can simplify the
problem into smaller areas in which to get relevant pharmacokinetic parameters.
These models integrate data from in vitro sources and physicochemical parame-
ters to create a physiologically based whole body model when using an ADME
basis (Lu¨pfert and Reichel, 2005). This is useful since it gives better realism in
pharmacological studies.
Poulin and Theil (2000) developed a method of predicting the tissue:plasma par-
tition coefficient using regression analyses. This has allowed PBPK modelling to
be used in earlier stages of drug discovery. This was not possible before because
predictions for new drug candidates could not be estimated as it was too time
consuming and cost intensive using QSPR and in vitro/vivo data.
PBPK modelling can be used to quantify the potential impact of pharmacokinetic
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aspects in inter-individual susceptibility (Clewell et al., 2002). The drawback to
using PBPK modelling is that the data are required a priori in order to develop
the model. If these data or other assumptions are faulty in any way, this can
cause the model to be invalid.
Drug discovery is not the only area of research this methodology is used for - it is
also used in risk assessment by government agencies such as the Environmental
Protection Agency (EPA) in the US (Chiu et al., 2007). This is because for toxi-
city studies it is sometimes not possible to measure the problem directly. PBPK
models are useful in these cases since they are independent of exposure route.
The advantage to this approach is that although it requires a large amount of pa-
rameters and physiological data specific to the species and compound, the model
is applicable to all mammalian species (Leahy, 2004).
An example of PBPK modelling is given in the work of Keys et al. (2003) in an
attempt to model Trichloroethylene (TCE) in rats and mice. A six-compartment
model is used, which includes the lung, slowly and rapidly perfused tissues, fat,
kidney and liver. This chemical has been extensively studied over the past 25
years and the paper covers different models used, both compartmental and PBPK.
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Chapter 3
Compartment Models
3.1 Introduction
This type of modelling is widely used in pharmacokinetics, as it is a means of re-
ducing complexity in drug metabolism problems. The simplest model is one with
a single well-mixed compartment, which is used mostly to describe intravenous
administrations since transfer into the blood system is assumed to be 100%. As
such there is no need for an absorption phase to be taken into account such as
there would be with oral or intraperitoneal administrations. This is due to the
need for the oral drug to be absorbed through the Gastro-Intestinal (GI) tract
membranes (Smith et al., 2001) and the intraperitoneal injection needs to pass
out of the peritoneal membrane surrounding the abdominal cavity.
Recently there has been a focus on Whole Body models since this approach would
give a better idea of where the metabolism takes place if all systems are taken
into account (Lu¨pfert and Reichel, 2005). As such compartments are assigned to
the lungs, heart, liver, kidney etc. and pharmacokinetic parameters for each are
found experimentally or assigned arbitrarily. Techniques for retrieving this data
are usually done in vitro with some more recent studies doing experiments in
vivo (Lombardo et al., 2002) as well since converting parameters (Baranczewski
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et al., 2006) from one to the other have been unreliable (Chiu et al., 2007). Other
methods include trying to find parameters by reproducing a verified set of data
(Curis et al., 2009). The other problem for this experimental data is that some-
times the particular animal used is not a good representative of the modelled
animal. For example, using rat data to predict parameters for a human model
(Harris and Barton, 2008) may be partially similar in mechanism in the body
but the differences could cause errors in the estimation and therefore a better
understanding is needed to account for these.
Grass (1997) used a two compartment STELLA (Structural Thinking Experimen-
tal Learning Laboratory with Animation) model in order to analyse the drugs
ketorolac and ganciclovir. This model is a physiologically based formulation used
to describe dynamics in the gastro-intestinal tract. The parameters were simu-
lated from in vitro data including animal cultures and used to predict oral drug
absorption in humans.
A review of modelling techniques including oral administrations with respect to
metal metabolism is outlined in Curis et al. (2009). This paper outlines the ad-
vantages and disadvantages of different models as well as the need for ”dummy”
compartments that have no strict use as they represent the absorbed from and ex-
creted to compartments. The paper presents the mammalian model for humans,
which is generally a compartment representing blood or plasma with peripheral
sections for organ systems that are relevant to the drug in question.
Doan and Boje (2000) analyse several different pharmacokinetic models with
reference to the endogenous inhibitors and their effect on drug half-lives and
concentration. They investigate this by using compartment models and different
administration techniques for the inhibitor. This includes oral and bolus with the
oral ingestion of food, which contain the inhibitor. The parameters in this case
were found using data from literature sources from experiments on rats which
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were given aspartame.
The oral administration of CHS 828, a cancer agent on rats, was analysed by
Friberg et al. (2005) using a one-compartment model. The study investigated
the effect of change of therapeutic schedule on drug efficacy on breast cancer cell
lines.
Flynn et al. (1996) used a Physiologically Based Pharmacokinetic (PBPK) model
with a number of compartments in order to analyse ethanol metabolism in mice
after an intraperitoneal injection. This approach uses mass balance equations to
track both parent and metabolite compounds over time per compartment. This
allows a greater insight into the effect of certain organ systems on ethanol concen-
tration. This approach is still used within this area of research although better
parameter estimates are still needed (Ramchandani et al., 2001).
Unlike the previous example, Yu et al. (1999) used a one-compartment model
for the metabolites in their experiments. They were investigating Cyclophos-
phamide and Ifosfamide in rats with reference to Cytochrome P450 catalysed
metabolism with respect to phenbarbital pre-treatment. These drugs were given
as intraperitoneal injections but since they were modelling the metabolites, the
one compartment approach is equivalent to a two compartment approach since
there is a phase of metabolism prior to the data used.
3.1.1 Administration techniques
The experimental data provided by CXR Biosciences were taken from procedures
on both Hepatic Reductase Null (HRN) and wild type mice (three of each). The
drugs were given through intraperitoneal injection and oral administration. An
intraperitoneal injection is used in experiments on small rodents since they are
very small and so have limited muscle mass and small veins (Fox et al., 2006). As
such it is easier to inject into the peritoneum since intravenous and intramuscular
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administrations are not so possible. In the case of Tamoxifen, the drug is given
orally which means that all the drugs are subject to extravascular modelling and
as such need more than one compartment to describe the dynamics.
3.1.2 Wild-type and Hepatic Reductase Null mouse
HRN mice are missing the hepatic Cytochrome P450 system but bred so that they
are still viable and fertile. These mice are useful as they give one the opportunity
to study the metabolism pathways taken by the drug. Through this method it
is also possible to gain an insight as to whether the main metabolism of a drug
happens in the liver, gastro-intestinal tract, extrahepatically etc. An unexpected
consequence of deleting hepatic Cytochrome P450 reductase was the discovery
that the P450 content of the liver was increased by approximately a factor of five.
These mice help investigate the toxicokinetics of compounds which can show
the side effects associated with a drug. This is especially useful when the drug
has a narrow therapeutic window, for example, anti-cancer drugs (Henderson
et al., 2006). Cyclophosphamide has been pharmacokinetically examined using
the Cytochrome P450 reductase null mouse (Pass et al., 2005).
3.1.3 Specific Drugs
Data from experiments with the wild type and Hepatic Reductase Null mouse
were made available from CXR Biosciences. This was in order to help find out
the differences in metabolic properties for the two mice. There were ten sets of
drug data and these were for Caffeine, Dextromethorphan, Diclofenac, Gefitinib,
Imatinib, Midazolam, Omeprazole, Paclitaxel, Tamoxifen and Thalidomide.
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Caffeine
Caffeine is a naturally occurring substance found in a number of food products
including coffee, tea and alcoholic beverages (Wishart et al., 2006). It is also
available as a drug - as a stimulant or within analgesics since it increases various
numerous neurotransmitters (Kot and Daniel, 2008) and as such it can affect
behaviour in terms of mood and attention. It affects many different systems
in the human body causing relaxation in smooth muscle, increased heart rate
through cardiac muscle stimulation and also has a diuretic affect (Wishart et al.,
2006). It is metabolised by two isoforms of Cytochrome P450 (CYP) namely 1A2
(Lewis, 2000) which is found in the hepatic system. This drug was given as an
intraperitoneal injection to the mice and the dose was 1 mg of caffeine per kg
body mass (mg/kg).
Dextromethorphan
This drug can be found in a number of cold and flu remedies since it acts as a
cough suppressant by acting on the cough centre in the medulla (Wishart et al.,
2006). Dextromethorphan itself is not an addictive substance even though it is an
opiate analog (Ziaee et al., 2005) but has been increasingly abused by adolescents.
People who are dependent on illicit drugs like heroin and other opiates sometimes
use it in combination with them. This drug is absorbed from the gastrointestinal
tract quickly into the bloodstream and is subject to first pass metabolism through
the hepatic portal vein. As such the availability of this drug would be quite short
since its presence and that of its metabolites is short lived. The CYP enzymes
associated with this drug are 3A4 and 2D6 (Felmlee et al., 2008), which are found
in both hepatic and extrahepatic systems like the small intestine. The drug is
given as an intraperitoneal injection of 1 mg/kg dose.
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Diclofenac
This non-steroidal anti-inflammatory drug (NSAID) is used in the treatment
of rheumatic diseases like arthritis and as an analgesic to help with fevers and
headaches (Yang et al., 2006; Bort et al., 1999). It is supposed that its analgesic
properties come from desensitising prostaglandin controlled pain receptors. It
is also believed that action in the hypothalamus results in heat dissipation in
the body and therefore control of fevers (Wishart et al., 2006). The enzymatic
metabolism of this drug is controlled by CYP2C8 (Venkatakrishnan et al., 2001)
and CYP2C9 (Lewis, 2000), which are primarily found in the hepatic system.
The drug was administered by an intraperitoneal injection of 1 mg/kg.
Gefitinib
This drug is an epidermal growth factor receptor (EGFR) inhibitor and as such is
used to treat many human cancers (Chang et al., 2008). In lung and breast cancers
EGFR is overexpressed and this can lead to uncontrolled cell proliferation and
this is why this drug is important in cancer treatment. This drug is metabolised
by CYP3A4 (Scripture et al., 2005), which means this must take place in the
liver or small intestine since this is where this enzyme can be found. As with
the previous drugs the substance is injected into the peritoneum with a dose of
5 mg/kg.
Imatinib
This antineoplastic agent is used in the treatment of Chronic Myelogenous Leukaemia
(CML) and GastroIntestinal Stromal Tumours (GISTs) (Wishart et al., 2006).
It inhibits tyrosine kinase activity for Platelet Derived Growth Factor (PDGF)
and Stem Cell Factor (SCF) and inhibits proliferation and induces apoptosis in
GISTs (Breccia and Alimena, 2009). When it comes to metabolising enzymes
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there are five that are associated with the possible breakdown of this substance
and these are the CYP enzymes: 1A2, 3A4, 2C9, 2C19 and 2D6 (van Schaik,
2008; Scripture et al., 2005). The intraperitoneal injection is given with a dose
level of 10 mg/kg.
Midazolam
This drug is a short-acting hypnotic-sedative drug that is commonly used in
dentistry, endoscopy and in combination with local anaesthesia (Wishart et al.,
2006). It is frequently used in palliative care as a sedative or anticonvulsant
(Morita et al., 2003). It is supposed to be used over short periods of time with the
longest time of use reported being 35 days. It is a benzodiazepine that acts as a
central nervous system depressant and as such has pharmacodynamic properties
including amnesia and sedation (Wishart et al., 2006). It increases (gamma)-
amino butyric acid (GABA) activity, which causes a calming effect resulting in
sleep. This drug is metabolised by CYP3A4 (Lewis, 2000) that is found in the
liver and small intestine. As with the previously mentioned drugs this is given
by intraperitoneal injection of 1 mg/kg.
Omeprazole
This drug inhibits the gastric acid secretion in order to treat gastro-duodenal
ulcers (Bosch et al., 2007) and works to eradicate the Helicobacter pylori when
combined with other drugs (Kuipers and Klinkenberg-Knol, 1999) as restriction
of acid is only one attack against this bacterium. In removing this bacterium it
reduces the possibility of ulcer recurrence (Wishart et al., 2006). The Cytochrome
P450 enzymes associated with the metabolism of this drug are 2C19 (Lewis, 2000)
and 2C8 (Mart´ınez et al., 2005). CYP2C19 is polymorphic and as such can cause
issues when it comes to drug therapy since a poor metaboliser would either have
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a reduced or heightened reaction to the drug. In the case of Omeprazole the poor
metabolisers have a better response when it comes to the removal of H. pylori
(Rogers et al., 2002) since it causes the drug to have a better efficacy due to
slower metabolism. This drug is given through an intraperitoneal injection of 1
mg/kg.
Paclitaxel
Paclitaxel (or Taxol) was first reported in a paper by Wani et al. (1971) and it
was isolated from the pacific yew tree and the antileukemic and tumour inhibitory
activity was suggested due to structure. It is associated with the therapy of
ovarian, breast and various other cancers (Wishart et al., 2006). As a compound
it has unfavourable properties such as low permeability and solubility and as
such it is poorly absorbed from oral administration (Choi et al., 2006). The CYP
enzymes associated with Paclitaxel metabolism are 3A4 (Scripture et al., 2005;
Smith et al., 2001) and 2C8 (Mart´ınez et al., 2005), which are found in the liver
and small intestine (3A4). The drug is given as an intraperitoneal injection of 10
mg/kg.
Tamoxifen
According to DrugBank Tamoxifen is a multi-functional compound acting as an
anti-estrogen in mammary tissue but can induce estrogen in cholesterol metabolism.
As such it belongs to the selective estrogen receptor modulators (SERMs) class
of drugs. This drug has been used in the fight against early and advanced breast
cancer for the past thirty years and as such has become a benchmark for up and
coming endocrine therapies to be measured against (Clemons et al., 2002). How-
ever this drug does have risk of developing endometrial carcinoma but this has
not stopped it from being the frontline treatment for hormone-responsive breast
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cancer (Singh et al., 2007). This drug is metabolised by six different CYP strains
- 1A2, 3A4, 2C9, 2D6, 2E1, and 2B6 (Scripture et al., 2005; Cozza et al., 2003;
Tredger and Stoll, 2002; van Schaik, 2008) - these strains are found both hepati-
cally and extrahepatically. This drug is given by oral administration at a dose of
10 mg/kg.
Thalidomide
This compound was initially used as a non-barbiturate hypnotic but it had to
be removed from distribution due to teratogenic effects. It is currently used for
inflammatory and immunological disorders as it shows immunosuppressive activ-
ity (Wishart et al., 2006). In addition to this it shows anti-angiogenic activity,
which might mean it can be used as part of cancer therapy. Although many of
the effects of the drug have been documented there is still a lot more information
about its mechanism of action required (Strasser and Ludwig, 2002). Recently
there has been research with zebrafish in Japan that has isolated the protein
that caused the birth defects in the children of Thalidomide patients (Ito et al.,
2010). The Cytochrome P450 enzyme responsible for Thalidomide metabolism is
2C19 (Ando et al., 2002) and this is found in the liver and is subject to polymor-
phisms as was mentioned with reference to Omeprazole. This drug was given by
intraperitoneal injection with a dose of 20 mg/kg.
3.2 Mathematical Models and Method
Three different compartment models were applied to the ten sets of drug data.
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3.2.1 Model 1: One Compartment
The first model from the sequential compartment models considers only one com-
partment y. This compartment represents the bloodstream in a normal intra-
venous dosing experiment i.e. that there is 100% transference of drug into the
body no loss. This assumption enables us to solve the ordinary differential
equation explicitly, returning an exponential decay solution. The drug is simply
eliminated at a given rate and no passage from one compartment to another takes
place (since there is only one compartment).
Figure 3.1: Schematic diagram of the one compartment model.
Using the Law of Mass Action, we obtain the following differential equation
and general solution:
dy
dt
= −k10y (3.1)
y = y(0)e−k10t (3.2)
The k10 and y(0) parameters were found using these explicit solutions with the
non-linear least squares algorithm in the R statistical software. Although this is
a very simplistic model, it gives a good way of evaluating the need for complexity
in future models.
3.2.2 Model 2: Two Compartments
This model is slightly more accurate than the previous model, since now the drugs
have an extravascular drug method either intraperitoneal or oral administration.
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As such there should be an absorption phase into the bloodstream and then an
elimination/excretion curve.
Figure 3.2: Schematic diagram of the two compartment model.
Once again, using the Law of Mass Action, the ordinary differential equations
for the above model are:
dy1
dt
= −k12y1 (3.3)
dy2
dt
= k12y1 − k20y2 (3.4)
Within this model y1 and y2 represent the primary dosing site (e.g. mouth in
oral administration) and the bloodstream respectively. The raw data is taken to
represent the y2 concentration. The explicit solutions for y1 and y2 are:
y1(t) = y1(0)e
−k12t (3.5)
y2(t) =
k12y1(0)(e
−k20te−k12t)
k12 − k20 (3.6)
This model is slightly more complicated than model 1 but it does have the right
phases, which is necessitated under the dosage methods.
3.2.3 Model 3: Three Compartments
This model further extends model 2 through an extra compartment. The config-
uration and ordinary differential equations for this model are as follows:
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Figure 3.3: Schematic diagram of the three compartment model.
dy1
dt
= −k12y1 (3.7)
dy2
dt
= k12y1 − k23y2 + k32y3 − y4 (3.8)
dy3
dt
= k23y2 − k32y3 (3.9)
dy4
dt
= a (3.10)
In this model the first and second compartments represent the same as in the
previous model i.e. y2 represents the bloodstream and y1 the injection/dose site.
As we can see there is a rate of absorption into the main compartment (y2)
indicated by k12. From the main compartment there are two ways for the drug
to be distributed – it can be passed into compartment three or be expelled from
the system entirely. The expulsion rate from the main compartment is time
dependent which means that if a is positive the rate increases as time increases
and vice versa for when a is negative. Currently a is being taken as positive only.
Compartment three represents lipid in the liver i.e. k23 is the rate at which the
drug is stored and k32 is the rate at which it is released back into the system. The
current assumption is that k23 >> k32 i.e. that it is easier to get into compartment
three than it is to leave.
The explicit solutions for this system are (including y2 which was used to fit using
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non-linear least squares to get the parameter values):
y1(t) = y1(0)e
−k12t (3.11)
y2(t) =
1
2
(k32 + k23)
−3(−k32 − k23 + k12)−1((2k223e−(k32+k23)ta+ 2e−k12ty1(0)k432
+ 2k332k12y1(0) + at
2k432 − k332at2k12 − 2k23k12e−(k32+k23)ta+ 2k323e−(k32+k23)tk12y1(0)
− 2y1(0)k432 − 2e−k12ty1(0)k332k12 + 2k23e−(k32+k23)tak32 + 2k23atk232
+ 2k23e
−(k32+k23)tk12y1(0)k232 + 4k
2
23e
−(k32+k23)tk12y1(0)k32 − 2k23atk32k12 + k323at2k32
+ 3k223at
2k232 + 3k23k
3
32at
2 − k223at2k12k32 − 2k23k232at2k12 − 2k23ak32 + 2k23ak12
+ 2ak323t− 2ak223 + 4ak32tk223 − 2ak223tk12 − 2k323y1(0)k32 − 6y1(0)k332k23 − 6k223y1(0)k232
+ 2k223k12y1(0)k32 + 4k12y1(0)k
2
32k23 + 6e
−k12tk223y1(0)k
2
32 + 2e
−k12tk323y1(0)k32
+ 6e−k12ty1(0)k332k23 − 2k323e−k12tk12y1(0)− 6k223e−k12tk12y1(0)k32 − 6e−k12tk12y1(0)k232k23)
(3.12)
y3(t) =
1
2
(k32 + k23)
−3(−k32 − k23 + k12)−1((−2y1(0)k332 − 2e−(k32+k23)tk23a+ k323at2
− 6k223y1(0)k32 − 2k323y1(0)− 2k223at+ 2k12ak32t− k12k232at2 − 2k23k32at2k12
− 2ak12 + 2e−(k32+k23)tk12y1(0)k223 − 2k12k232e−(k32+k23)ty1(0) + 2k23a− 2k32e−(k32+k23)ta
− 2k232at− 4k12k32k23e−(k32+k23)ty1(0)− 6y1(0)k232k23 + 2ak32 − 4k23atk32
+ 2e−k12ty1(0)k332 + 3k
2
23at
2k32 − k223at2k12 + 3k23k232at2 + 2k23ak12t− 2e−(k32+k23)tak12
+ 4k32k12y1(0)k23 + 6e
−k12tk223y1(0)k32 + 6e
−k12tk23y1(0)k232 + 2k
2
23k12y1(0)
+ 2e−k12tk323y1(0) + 2k12y1(0)k
2
32 + k
3
32at
2)k23) (3.13)
y4(t) = at (3.14)
3.3 Results
For each drug the model parameters are compared and contrasted with the Wild
Type (WT) and HRN mouse. The plots show the average drug data (over three
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mice) and the fitted model. The fit was assessed using the Akaikes Information
Criterion (AIC) and a paired t test on each average data set compared with the
each of the fitted models. The t test was also used with each mouse individually
to see whether the average data was truly representative of the mice. The Akaikes
Information Criterion is defined as:
AIC = 2k − 2log(L) (3.15)
Where k is the number of parameters used to fit the model and L is the likelihood
function. For this statistic the smaller and more negative the AIC the better the
fit of the model. The paired t test is a hypothesis test using the t-distribution on
the following:
H0 := d¯ = 0 (3.16)
H1 := d¯ 6= 0 (3.17)
For the purposes of this thesis the t probability values will be taken from a
t61−1 = t60 distribution. The test statistic is:
T =
d¯
s.e.√
n
(3.18)
Where d¯ represents the average of the differences between the two data point sets,
s.e. stands for the standard error of the differences and n is the number of data
points. If the individual tests have similar results to that of the average then
stronger conclusions can be drawn from the models than if the test statistics are
very different from the average statistic. As well as these tests it was necessary
to test the assumption for using non-linear least squares for fitting the parame-
ters. This assumption is that the residuals are distributed normally and this was
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assessed using a Shapiro-Wilks test in combination with a Quartile-Quartile plot
(this is because the test lacks power). A runs test (which analyses systematic
deviance from the model) was also run from the nls testing suite in R.
3.3.1 Caffeine
The model parameters for this drug are shown in table.
Parameters WT HRN Ratio (3dp) S-W QQ Runs
Model 1
y(0) 1662.21 1810 1:1.089
3 3 3
k10 0.7471755 0.0517 1:0.069193918
Model 2
y1(0) 1656.924 2063.533 1:1.245
3 3 3k12 234.9226 6.631757 1:0.028
k20 0.7471753 0.08870665 1:0.119
Model 3
y1(0) 1654.457 2035.918 1:1.231
3 3 3
k12 129.4292 6.821051 1:0.053
k23 0.7506233 0.07261716 1:0.097
k32 0.002020398 0 1:0
a 0 7.6506 0:1
Table 3.1: Caffeine Model Parameters and outcomes at the 5% level from the Nor-
mality Assumption tests (S-W = Shapiro-Wilks Test and QQ = Quartile-Quartile Plot)
and Runs Test.
The normality assumption is satisfied in all three fitted models plus there is
no evidence from the runs test of systematic deviance in the data from the fitted
models.
Model 1
For model 1 there is a large difference between the k10 parameter values - the
excretion rate is roughly 7% of the value in the HRN model than the WT. As
well as this difference there is an increase in the initial value in the compartment
of about 8.9% between the WT and HRN models.
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Figure 3.4: Plots showing the Caffeine drug concentration against time for the raw
data (5) and computational simulation results (solid line) from Model 1.
The fit for the Wild Type mouse model is much better than that of the HRN
mouse. This suggests that the drug activity could be assessed as excretion only
for the WT mouse but has some absorption in the HRN mouse.
Model 2
For model 2 the parameters show a large difference between the WT and HRN
mouse. The transfer rate between the two compartments, which represents ab-
sorption, in the HRN is roughly 2.8% of the rate that is apparent in the WT.
However the excretion rate is approximately 11.9% of the magnitude in the Hep-
atic Reductase Null mouse than that of the Wild Type. For the initial concen-
tration in compartment 1 there is a 24.5% increase in value for the HRN model
in comparison to the WT.
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Figure 3.5: Plots showing the Caffeine drug concentration against time for the raw
data (5) and computational simulation results (solid line) from Model 2.
For this model, the fit for both sets of data is good but since the WT data
shows a very fast absorption rate this means that the model has been fitted with
a pointed peak.
Model 3
In model 3 all the parameters have been chosen so that the visual fit is better.
The parameter k12 shows that the absorption rate in the HRN mouse is 5.3% of
that of the normal WT mouse. This suggests that the absorption of Caffeine into
the bloodstream (y2) occurs at a reduced rate in the HRN mouse. The transfer
rates into and away from compartment y3 (k23 and k32) represent a delay in the
system. For k23 there is a marked difference being roughly a tenth of the WT
value in the HRN model but for k32 the values are very small with the value in
the HRN being zero. This means that for caffeine both mouse types show that it
is easier to get into compartment y3 than leaving it, which is the original assump-
tions of the model. For the time dependent excretion rate out of the bloodstream
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(y4) the parameter values have a similar shift to that of k32 i.e. the WT value
is zero and the HRN is non-zero. As with the other two model configurations
there is a difference in initial concentration for compartment 1 - in this model
this change is a 23.1% increase in the HRN model.
Figure 3.6: Plots showing the Caffeine drug concentration against time for the raw
data (5) and computational simulation results (solid line) from Model 3.
The fitted model follows the behaviour for both the wild type and HRN av-
erage mouse data quite effectively.
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Data Average Model 1 Model 2 Model 3
HRN -
0.99561641 0.981338625 0.97907404
100.3834 75.63368 78.56304
Mouse 1 0.07697907 0.149111088 0.026101267 0.026044594
Mouse 2 0.083316555 0.130935742 0.036826644 0.036278197
Mouse 3 0.836869228 0.885573384 0.778813372 0.777755126
WT -
0.95614507 0.956147316 0.999998332
74.46273 76.46273 80.44003
Mouse 4 0.675740077 0.901204918 0.90120611 0.925762665
Mouse 5 0.037645727 0.010019816 0.010019833 0.011451952
Mouse 6 0.065269961 0.042006574 0.042006532 0.038551134
Table 3.2: Caffeine - Paired t Test p-values and AIC (Akaike’s Information Criterion)
values.
From this table the results of paired t tests between the average data can be
seen, fitted values from each of the models and the data from each mouse either
HRN or WT. The comparison test between the average data and each mouse
gives an indication of how well the average data emulates the behaviour of the
mice. The AIC values allow the fit to be assessed while taking into account the
number of parameters used to fit the model.
For the WT mouse the model that best fits is model 1 since it has the smallest
AIC value even though the paired t test shows that the data from all three fitted
models show a non-significant result (do not reject H0 : d¯ = 0) when compared to
the average data. For the HRN mouse, model 2 is the best for the same reasons.
From the table it can be seen that the average raw data differs significantly for
mouse 5 in comparison to the WT average mouse data.
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3.3.2 Dextromethorphan
The model parameters for this drug are:
Parameters WT HRN Ratio (3dp) S-W QQ Runs
Model 1
y(0) 71.6441 72.27797 1:1.009
3 3 3
k10 0.5907 0.29669 1:0.502
Model 2
y1(0) 71.60792 78.4644 1:1.096
3 3 3k12 1169.469 9.19685 1:0.008
k20 0.5907452 0.352626 1:0.597
Model 3
y1(0) 70.87566 2336.9234 1:32.972
3 3 3
k12 263.1207 0.3181 1:0.001
k23 0.5695108 9.6475 1:16.940
k32 0 0 1:1
a 0.2565778 5.3846 1:20.986
Table 3.3: Dextromethorphan Model Parameters and outcomes at the 5% level from the
Normality Assumption tests (S-W = Shapiro-Wilks Test and QQ = Quartile-Quartile
Plot) and Runs Test.
The normality assumption for the non-linear fitting is satisfied and the runs
test shows that there is no evidence of systematic deviance in all three models.
Model 1
For model 1 the initial values are similar but with a difference of 0.9% between
the HRN and wild type mouse. However for the parameter k10 the HRN value is
50.2% of the value suggesting that absorption is slower than in the WT.
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Figure 3.7: Plots showing the Dextromethorphan drug concentration against time for
the raw data (5) and computational simulation results (solid line) from Model 1.
The fit of this model for both sets of data is quite good however the HRN
data does show an absorption phase.
Model 2
The parameters for the model show differences between the HRN and WT mice.
The parameter values are all smaller for the HRN in comparison to the wild type.
The initial concentrations differ by a factor of 9.6%, the absorption by 0.8% and
elimination by 59.7%.
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Figure 3.8: Plots showing the Dextromethorphan drug concentration against time for
the raw data (5) and computational simulation results (solid line) from Model 2.
The fit of these models to the raw data is good since there is similarity in
behaviour.
Model 3
For the model 3 parameters the initial concentration in the HRN is roughly 33
times that of the WT and time dependent excretion is roughly 21 times. When it
comes to the parameters associated with compartment 3 (k23 17 times the value
in HRN than in WT and k32 is zero in both mice. The absorption parameter k12
is 0.1% of the wild type value in the transgenic mouse.
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Figure 3.9: Plots showing the Dextromethorphan drug concentration against time for
the raw data (5) and computational simulation results (solid line) from Model 3.
The fit of this model to both mouse datasets is good. The behaviour of the
averaged data shows two peaks, which is not shown through the fitted model.
This shows that another time scale may be involved in the metabolism of this
drug.
Data Average Model 1 Model 2 Model 3
HRN -
0.880505718 0.940079609 0.998254187
48.57802 40.85807 44.39718
Mouse 1 0.022137418 0.039685659 0.022994648 0.02426086
Mouse 2 0.063085991 0.090636072 0.090340626 0.086546615
Mouse 3 0.1298626 0.107750331 0.090819984 0.081782114
WT -
0.856740187 0.856741514 0.988181302
42.85487 44.85487 48.52601
Mouse 4 0.034496768 0.119793258 0.119793021 0.097660591
Mouse 5 0.205744262 0.223123768 0.223123853 0.254867031
Mouse 6 0.90150981 0.848116361 0.848116885 0.891413375
Table 3.4: Dextromethorphan - Paired t Test p-values and AIC (Akaike’s Information
Criterion) values.
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For this drug all three fitted models show non-significant results for the paired
t test at the 5% level when compared to the average data. The AIC values suggest
that model 2 is best for the HRN data whereas model 1 is best for the WT data.
When it comes to comparing the mice to the average data one mouse of each type
fails to show similarity (mouse 1 and mouse 4).
3.3.3 Diclofenac
For this drug the model parameters are:
Parameters WT HRN Ratio (3dp) S-W QQ Runs
Model 1
y(0) 2550.1905 2499.7354 1:0.980
3 3 3
k10 2.492 2.6666 1:1.070
Model 2
y1(0) 2508.16 2346.5682 1:0.936
3 3 3k12 147.927 42.4162 1:0.287
k20 2.491993 2.6703 1:1.072
Model 3
y1(0) 257538799 11508.58 1:4.469E-05
3 3 3
k12 3.052991 3.573899 1:1.171
k23 286084.9 16.13086 1:5.638E-05
k32 0.1549957 0.1641611 1:1.059
a 4658412 205.6111 1:4.414E-05
Table 3.5: Diclofenac Model Parameters and outcomes at the 5% level from the Nor-
mality Assumption tests (S-W = Shapiro-Wilks Test and QQ = Quartile-Quartile Plot)
and Runs Test.
As can be seen from the final three columns the assumption of normality is
valid and the data does not show systematic deviance from any of the models.
Model 1
For model 1 the HRN mice parameter values are roughly the same as that of the
WT. For the initial concentration this value is 98% of the wild type and for the
excretion rate it is an increase of 7%.
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Figure 3.10: Plots showing the Diclofenac drug concentration against time for the
raw data (5) and computational simulation results (solid line) from Model 1.
The fit of this model is good at the start of the time period but not at the
end where the fitted value is roughly half of the raw data.
Model 2
In the second model the parameters are quite different between the wild type and
HRN mouse. For the initial concentrations the HRN model has a y(0), which is
93.6% of the wild type value. The HRN excretion rate however is 7.2% larger
and the absorption rate is 28.7% of the wild type value.
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Figure 3.11: Plots showing the Diclofenac drug concentration against time for the
raw data (5) and computational simulation results (solid line) from Model 2.
This calculated model shows a jagged fit due to the very quick absorption and
then the fit after the first hour is similar to that of model 1. This could be due
to a change in time scale dynamics i.e. fast to slow.
Model 3
For the three-compartment model y(0), k23 and a show large differences between
the sets of data. The difference between the other parameters is only slight - k12
changes by +17.1% and k32 by +5.9% from WT to HRN.
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Figure 3.12: Plots showing the Diclofenac drug concentration against time for the
raw data (5) and computational simulation results (solid line) from Model 3.
The fit of model 3 is the best with the only deviation between the fitted model
and raw data occurring between the 1-hour and 2 hours point.
Data Average Model 1 Model 2 Model 3
HRN -
0.267219905 0.265622061 0.990714102
77.7824 79.78205 72.20395
Mouse 1 0.404437319 0.449800586 0.450939415 0.199901248
Mouse 2 0.085136337 0.14465255 0.145057985 0.042948243
Mouse 3 0.175618483 0.053122993 0.052942053 0.09035055
WT -
0.292265579 0.296993807 0.989312594
80.51012 82.51036 75.0641
Mouse 4 0.033234243 0.033312079 0.0336501 0.05065298
Mouse 5 0.180834146 0.067872001 0.067994106 0.17323143
Mouse 6 0.05215308 0.181932753 0.181661341 0.062368356
Table 3.6: Diclofenac - Paired t Test p-values and AIC (Akaike’s Information Crite-
rion) values.
The comparison test statistics between the averages and the raw mouse data
shows that for all but mouse 4 the average is similar enough to base the fitted
models on. As well as this the AIC values suggest that the best model is model
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3 for both sets of data, which is consistent with the visual results.
3.3.4 Gefitinib
The model parameters for this drug are:
Parameters WT HRN Ratio (3dp) S-W QQ Runs
Model 1
y(0) 1556.875 815.99724 1:0.524
3 3 3
k10 0.4150626 0.12386 1:0.298
Model 2
y1(0) 1576.433 846.402 1:0.537
3 3 3k12 15.68056 11.28965 1:0.720
k20 0.4466992 0.14112 1:0.316
Model 3
y1(0) 2106.7788 1162.9358 1:0.552
3 3 3
k12 8.176 6.1506 1:0.752
k23 1.2761 0.9836 1:0.771
k32 0.5854 1.1665 1:1.993
a 61.0799 22.4509 1:0.368
Table 3.7: Gefitinib Model Parameters and outcomes at the 5% level from the Nor-
mality Assumption tests (S-W = Shapiro-Wilks Test and QQ = Quartile-Quartile Plot)
and Runs Test.
As with Diclofenac the Normality assumption tests and the systematic de-
viance test show that it is fine to perform non-linear least squares as a fitting
mechanism.
Model 1
In the first model the initial concentration for HRN is 52.4% of WT and for the
elimination parameter k10 this figure is 29.8%.
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Figure 3.13: Plots showing the Gefitinib drug concentration against time for the raw
data (5) and computational simulation results (solid line) from Model 1.
The fit for the wild type model is far better than for the HRN mouse although
both sets of data show an absorption phase, which is not present in model 1.
Model 2
For model 2 the initial concentration for the HRN mouse is 53.7% of the wild
type value. For the absorption parameter, k12, the value is 72% of the WT value
and the elimination, k20, is 31.6% of the wild type mouse.
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Figure 3.14: Plots showing the Gefitinib drug concentration against time for the raw
data (5) and computational simulation results (solid line) from Model 2.
For both these models the fit to the raw data is quite good although there are
dynamics in the data not catered for in the second model.
Model 3
From inspecting the parameters for model 3 there are some differences. The ini-
tial concentration for the HRN is 55.2% of the WT value and the absorption is
75.2% of the parameter. The associated parameters to the third compartment in
the HRN mouse show differences from those in the wild type: for k23 is 77.1%
of the value whereas k32 is almost 2 times larger. However the time dependent
excretion parameter, a, is 36.8% in the HRN mouse.
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Figure 3.15: Plots showing the Gefitinib drug concentration against time for the raw
data (5) and computational simulation results (solid line) from Model 3.
As with model 1 the WT data is fitted much better than the HRN data but
this is mainly to do with the bimodal nature of this drugs data in the transgenic
mouse.
Data Average Model 1 Model 2 Model 3
HRN -
0.999594586 0.985005622 0.988800895
108.1072 107.0117 108.6244
Mouse 1 0.080937265 0.08469173 0.121725624 0.181555724
Mouse 2 0.00148069 0.011728021 0.008528618 0.002077877
Mouse 3 0.001821999 0.024289635 0.012023015 0.006675974
WT -
0.794259624 0.703273292 0.983612415
114.1636 115.0288 99.98192
Mouse 4 0.041612408 0.065304589 0.044939771 0.044394383
Mouse 5 0.21263057 0.632297258 0.675789972 0.145500062
Mouse 6 0.106517141 0.533764116 0.567128413 0.230323713
Table 3.8: Gefitinib - Paired t Test p-values and AIC (Akaike’s Information Criterion)
values.
For the average data the fit from the paired t test is good for all models but
for three of the mice (mouse 2, 3 and 4) the average is not representative at
56
the 5% level. The AIC values suggest that the best model for the HRN mouse
is model 2 whereas for the WT this is the third model. The average data for
the HRN mouse shows at least two peaks, which are not features of any of the
compartment models considered.
3.3.5 Imatinib
For this drug the parameters for all the models are:
Parameters WT HRN Ratio (3dp) S-W QQ Runs
Model 1
y(0) 7943.4099 7434.8036 1:0.936
3(W) 7(H) 3 3
k10 2.3915 2.4251 1:1.014
Model 2
y1(0) 7811.754 7021.7975 1:0.899
3(W) 7(H) 3 3k12 144.2846 42.5696 1:0.295
k20 2.391542 2.4282 1:1.015
Model 3
y1(0) 8672.75 7541.525 1:0.870
3 3 3
k12 855075.8 16.33991 1:1.911E-05
k23 2.83568 3.068934 1:1.082
k32 0.1520032 0.1473011 1:0.969
a 179.5087 151.2954 1:0.843
Table 3.9: Imatinib Model Parameters and outcomes at the 5% level from the Nor-
mality Assumption tests (S-W = Shapiro-Wilks Test and QQ = Quartile-Quartile Plot)
and Runs Test.
As can be seen from the table above there is a problem with the normality
assumption for the first two models applied to the HRN data. However since the
test on this assumption is done in conjunction with the Quartile-Quartile plot it
is still possible to use non-linear least squares to fit these data. All of the wild
type models and the third HRN model obey all the assumptions.
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Model 1
For model 1 the rate constant k10 is very similar between the two datasets with
a change of only 1.4%. However the main change is between the initial concen-
trations where the HRN y(0) is 93.6% of the WT value.
Figure 3.16: Plots showing the Imatinib drug concentration against time for the raw
data (5) and computational simulation results (solid line) from Model 1.
The fit of this model is fine up until the one-hour point but at the end the
concentration is half what the raw data is.
Model 2
In the second model the HRN concentration at the start is 89.9% of the wild type
value. The transfer rate between the two compartments, k12, is calculated to be
29.5% of the WT value in the HRN mouse. However the elimination rate is very
similar, the HRN being only 1.5% faster than in the wild type mouse.
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Figure 3.17: Plots showing the Imatinib drug concentration against time for the raw
data (5) and computational simulation results (solid line) from Model 2.
As with Diclofenac the fit of this model to the data in the first two hours is
good but is poor after this point.
Model 3
For the three-compartment model the initial concentration in the transgenic
mouse is 87% of the wild type level. There is a large difference in absorption
rate but all other parameters do not have such a big deviation. For the third
compartment parameters the input is 8.2% faster in the HRN and the output
rate is a 96.9% of the wild type level. The time dependent excretion is 84.3%,
this is slower than in the wild type mouse.
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Figure 3.18: Plots showing the Imatinib drug concentration against time for the raw
data (5) and computational simulation results (solid line) from Model 3.
The model fit is good for both sets of data. However in the wild type plot the
peak is jagged suggesting too quick a transition from absorption to elimination
in the parameter set.
Data Average Model 1 Model 2 Model 3
HRN -
0.450171095 0.448021251 0.993331183
122.2021 124.2018 122.5585
Mouse 1 0.095278266 0.059279436 0.059224358 0.096649954
Mouse 2 0.081393718 0.266882155 0.267162233 0.113754151
Mouse 3 0.123483884 0.333740222 0.334438738 0.162144015
WT -
0.343849948 0.34387883 0.994015349
125.8037 127.8037 123.1115
Mouse 4 0.014543334 0.134026753 0.134024074 0.021273337
Mouse 5 0.04327831 0.010216045 0.010215945 0.035740117
Mouse 6 0.291020438 0.856229138 0.856208787 0.442361628
Table 3.10: Imatinib - Paired t Test p-values and AIC (Akaike’s Information Crite-
rion) values.
According to the paired t test with the average data all models are similar
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to the observed data at the 5% level. When comparing the raw mice data with
the average only two of the mice (mouse 4 and 5) do not show similarity in the
test. The AIC values suggest that the best model for the HRN data is the first
model. However since this model had a significant result in the Shapiro-Wilks
test (non-normal residuals) it is better using the third model since the AIC value
for this is comparable. For the wild type data the best model is the third one
and this showed a good level of visual fit with the data.
3.3.6 Midazolam
For the three models for this drug we have the following parameters:
Parameters WT HRN Ratio (3dp) S-W QQ Runs
Model 1
y(0) 111.4156 170.2512 1:1.528
3 3 3
k10 0.9694 0.3994 1:0.412
Model 2
y1(0) 130.9995 207.87443 1:1.587
3 3 3k12 8.7775 6.27233 1:0.715
k20 1.3763 0.58136 1:0.422
Model 3
y1(0) 162.5598 212.72045 1:1.309
3 3 3
k12 6.31 6.03469 1:0.956
k23 2.0968 0.62637 1:0.299
k32 0.1971 0.04408 1:0.224
a 3.2448 1.36268 1:0.420
Table 3.11: Midazolam Model Parameters and outcomes at the 5% level from the
Normality Assumption tests (S-W = Shapiro-Wilks Test and QQ = Quartile-Quartile
Plot) and Runs Test.
All three columns showing the results from the assumption check agree that
non-linear least squares can be used to fit these models to the data.
Model 1
As the ratio for the initial concentration for model 1 suggests the HRN mouse
has 1.528 times the amount of Midazolam starting in compartment 1. However
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with respect to the parameter k10 it is 41.2% of the value, suggesting a slower
excretion rate.
Figure 3.19: Plots showing the Midazolam drug concentration against time for the
raw data (5) and computational simulation results (solid line) from Model 1.
The fit of the model to this data is reasonable although there is definitely an
absorption phase that should be accounted for as per the second model.
Model 2
The transgenic mouse initial concentration is 1.587 times that of the wild type.
The HRN values for k12 and k20 are 71.5% and 42.2% of the WT respectively.
62
Figure 3.20: Plots showing the Midazolam drug concentration against time for the
raw data (5) and computational simulation results (solid line) from Model 2.
Although there is an absorption phase demonstrated by the data this be-
haviour is not mimicked closely enough by the fitted model especially after the
one-hour point.
Model 3
For the initial concentrations the difference is +30.9% from the WT to the HRN
values. The absorption parameter, k12, is nearly identical in the HRN and wild
type mouse since it is 95.6% the value. According to the ratios both compartment
3 parameters are smaller for the HRN mouse. It is a 29.9% the size for k23 and
22.4% for k32. The a parameter is also smaller in the HRN mouse at 44% the
wild type level.
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Figure 3.21: Plots showing the Midazolam drug concentration against time for the
raw data (5) and computational simulation results (solid line) from Model 3.
The model results in a good fit to the data with a slight difference only
occurring between the 2hr and 4hr points in the HRN and 1hr and 2hr points in
the wild type.
Data Average Model 1 Model 2 Model 3
HRN -
0.845128727 0.868274293 0.962974603
65.92079 35.40085 37.86993
Mouse 1 0.008537834 0.160864989 0.007911405 0.008793906
Mouse 2 0.346047952 0.751822893 0.283365543 0.303815977
Mouse 3 0.019639363 0.016451803 0.023642364 0.022096791
WT -
0.869871134 0.406401416 0.978943436
52.84141 46.82994 42.34225
Mouse 4 0.175962694 0.253692084 0.117791101 0.19005748
Mouse 5 0.01630903 0.163253623 0.078725595 0.00441406
Mouse 6 0.718358027 0.774532791 0.915624061 0.723533972
Table 3.12: Midazolam - Paired t Test p-values and AIC (Akaike’s Information Cri-
terion) values.
For these sets of data the goodness-of-fit test show that for mouse 1, mouse 3
and mouse 5 the average data does not emulate the same behaviour. However all
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three models fit the average data well according to the paired t test comparison.
According to the AIC values model 2 is the best for the HRN data and model 3
shows the best fit from the three models examined for the wild type.
3.3.7 Omeprazole
This drug has the following model parameters:
Parameters WT HRN Ratio (3dp) S-W QQ Runs
Model 1
y(0) 626.18439 941.0905 1:1.503
3 3 3
k10 5.45408 1.2607 1:0.231
Model 2
y1(0) 525.1421 5642.2077 1:10.744
3 3 3k12 28.8632 1.742 1:0.060
k20 5.5588 8.9964 1:1.618
Model 3
y1(0) 532.74888 1127.2856 1:2.116
3 3 3
k12 20.27684 8.5388 1:0.421
k23 6.0252 1.858 1:0.308
k32 0.02656 0.0421 1:1.585
a 2.14976 8.5514 1:3.978
Table 3.13: Omeprazole Model Parameters and outcomes at the 5% level from the
Normality Assumption tests (S-W = Shapiro-Wilks Test and QQ = Quartile-Quartile
Plot) and Runs Test.
As with Midazolam in the previous section the non-linear least squares algo-
rithm can be used due to residual normality and systematic deviation assumptions
being satisfied.
Model 1
In model 1 there is a large difference between the calculated initial concentrations
since HRN has a value about 1.5 times the WT constant. The k10 parameter is
smaller at 23.1% of the WT value.
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Figure 3.22: Plots showing the Omeprazole drug concentration against time for the
raw data (5) and computational simulation results (solid line) from Model 1.
For the HRN data the fit of this model is reasonable but there is an indication
of an absorption phase. For the wild type mouse the fit of this model to the data
is good.
Model 2
For this model the calculated starting values seem unusual since the wild type
value is comparatively small at 525.1421ng/mol whereas the HRN value is 10.744
times this according to the ratio. The two rate parameters are different as well -
k12 is 6% of the wild type value and k20 is 1.618 times in magnitude.
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Figure 3.23: Plots showing the Omeprazole drug concentration against time for the
raw data (5) and computational simulation results (solid line) from Model 2.
The fit for both sets of data is good, especially in the wild type plot.
Model 3
The starting values for this model differ by a factor of 2.116 in the HRN favour.
The other parameter that is increased is a showing roughly a four fold increase.
The absorption parameter k12 is 42.1% and k23 is 30.8% of their WT counter-
parts. Whereas k32 is 1.585 times larger than its wild type equivalent.
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Figure 3.24: Plots showing the Omeprazole drug concentration against time for the
raw data (5) and computational simulation results (solid line) from Model 3.
The fitted model for the WT mouse is better than the HRN since in its plot
it has a gaps between the two lines in the time period 1-2 hrs.
Data Average Model 1 Model 2 Model 3
HRN -
0.854680191 0.877093755 0.989060612
79.20484 69.5871 73.1831
Mouse 1 0.561316659 0.967884949 0.540672452 0.628406255
Mouse 2 0.033634637 0.076531815 0.045814346 0.034233958
Mouse 3 0.036175825 0.254645058 0.080387231 0.097132208
WT -
0.285873511 0.192530647 0.995394603
26.15958 27.80053 20.80836
Mouse 4 0.175784132 0.168025764 0.166611719 0.17576973
Mouse 5 0.132644192 0.145028751 0.147134361 0.132716795
Mouse 6 0.257919396 0.28146986 0.285949807 0.258179914
Table 3.14: Omeprazole - Paired t Test p-values and AIC (Akaike’s Information
Criterion) values.
With reference to the paired t test all the wild type and mouse 1 from the
HRN mice show similarity with the average data. The best model for the wild
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type data is model 3 whereas for the HRN mouse the second model is the top.
3.3.8 Paclitaxel
For this drug the model parameters are:
Parameters WT HRN Ratio (3dp) S-W QQ Runs
Model 1
y(0) 694.34851 476.45113 1:0.686
3 3 3(W) 7(H)
k10 0.07061 0.03066 1:0.434
Model 2
y1(0) 694.285 812.4896 1:1.170
3 3 3k12 805.5993 1.276029 1:0.002
k20 0.07060922 0.07387129 1:1.046
Model 3
y1(0) 3266.985 1448.483 1:0.443
3 3 3(W) 7(H)
k12 0.4601999 0.6898806 1:1.499
k23 0.460518 0.4584039 1:0.995
k32 0 0.2703421 0:1
a 0.04483011 10.65818 1:237.746
Table 3.15: Paclitaxel Model Parameters and outcomes at the 5% level from the
Normality Assumption tests (S-W = Shapiro-Wilks Test and QQ = Quartile-Quartile
Plot) and Runs Test.
With respect to the normality of the residuals all models for both sets of data
are fine. However the runs test has a significant result at the 5% level for the
HRN model 1 and 3, which suggests that the data systematically deviates from
the models.
Model 1
From the table above the parameters for model 1 are different between HRN and
WT. The initial concentration is 68.6% of the WT value and for k10 this level is
43.4%.
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Figure 3.25: Plots showing the Paclitaxel drug concentration against time for the raw
data (5) and computational simulation results (solid line) from Model 1.
Since both these plots show an absorption phase this model does not provide
a good enough fit.
Model 2
The initial concentration for the HRN mouse is 1.17 times the WT and k20 is also
larger by 4.6%. For k12 the parameter is smaller since this value is 0.2% of the
WT value in the HRN mouse.
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Figure 3.26: Plots showing the Paclitaxel drug concentration against time for the raw
data (5) and computational simulation results (solid line) from Model 2.
For the HRN mouse the fit is a lot better in comparison to model 1 but the
elimination part of the curve still differs. For the wild type the fit seems poor
since the curve does not follow the behaviour of the data.
Model 3
In model 3 the HRN initial value is 44.3% of the WT constant. The only param-
eter other than this showing a reduction in value is k23, which is 99.5% of the
WT level. The k12 parameter is +49.9% and a is 237.746 times the WT value.
The k32 value is different between the two mice as it is zero in the wild type and
0.27 in the HRN mouse.
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Figure 3.27: Plots showing the Paclitaxel drug concentration against time for the raw
data (5) and computational simulation results (solid line) from Model 3.
Given these changes in parameter value the WT model seems to fit the cor-
responding data better than the HRN although neither gives a very good fit.
Data Average Model 1 Model 2 Model 3
HRN -
0.962195496 0.793552517 0.893191317
137.7816 105.5475 106.0508
Mouse 1 0.251939365 0.23068858 0.215916235 0.234643429
Mouse 2 0.0630742 0.513246421 0.089454806 0.069459408
Mouse 3 0.786460194 0.936184518 0.867490755 0.831785634
WT -
0.914061936 0.914056865 0.436215134
154.7613 156.7613 139.792
Mouse 4 0.068164909 0.713677412 0.713672297 0.129054034
Mouse 5 0.192315621 0.958616557 0.95862171 0.761125341
Mouse 6 0.284894945 0.982517343 0.98251257 0.638383344
Table 3.16: Paclitaxel - Paired t Test p-values and AIC (Akaike’s Information Crite-
rion) values.
All the models and mice show similarity to the average data in the paired t
test at the 5% level. According to the AIC values the best model for the HRN
data is the second model and for the WT it is the third. This is congruent with
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the visual fit of these models and the fact that the first and third models are
unsuitable for the HRN data due to the significant Runs test.
3.3.9 Tamoxifen
The model parameters for this drug are shown in the following table:
Parameters WT HRN Ratio (3dp) S-W QQ Runs
Model 1
y(0) 105.58456 55.37275 1:0.524
3 3 3(W) 7(H)
k10 0.2125 0.02592 1:0.122
Model 2
y1(0) 120.28051 132.8924 1:1.105
3 3 3k12 6.15138 0.8996 1:0.146
k20 0.27348 0.1695 1:0.620
Model 3
y1(0) 129.3104 213.5103 1:1.651
3 3 3
k12 5.27876 0.5576164 1:0.106
k23 0.3712349 0.4473217 1:1.205
k32 0.05571804 0.1092564 1:1.961
a 0 0.3575627 0:1
Table 3.17: Tamoxifen Model Parameters and outcomes at the 5% level from the
Normality Assumption tests (S-W = Shapiro-Wilks Test and QQ = Quartile-Quartile
Plot) and Runs Test.
As with Paclitaxel, Tamoxifen HRN data shows systematic deviation from
model 1.
Model 1
For the first model the parameters are all lower in value for HRN in comparison
to WT. The initial concentration is 52.4% of the level and k10 is 12.2% of the rate.
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Figure 3.28: Plots showing the Tamoxifen drug concentration against time for the
raw data (5) and computational simulation results (solid line) from Model 1.
The fit for the WT model is reasonable although the formulation does not
allow the absorption phase shown in the data. The HRN model however has a
poor fit for the data.
Model 2
For this model the HRN model starts with a concentration 1.105 times that of
the WT starting value. The absorption parameter, k12, is 14.6% of the wild type
value and the elimination rate is 62%.
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Figure 3.29: Plots showing the Tamoxifen drug concentration against time for the
raw data (5) and computational simulation results (solid line) from Model 2.
The fit for the WT data is better than that for the HRN data. There is
disparity between the HRN model and the raw data between the 7hr and 24hr
points but this is more due to a lack of points between.
Model 3
Initially the HRN third model starts with 65.1% more Tamoxifen in the first com-
partment. The wild type model has a transfer rate between the first and second
compartment that is ten times that of the HRN. When it comes to the third sec-
tion the rate of transfer into it is +20.5% of the WT value and the opposite flow
is also quicker by 96.1%. In the wild type mouse the time dependent elimination
is zero but it is larger in the HRN mouse with a level of 0.34.
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Figure 3.30: Plots showing the Tamoxifen drug concentration against time for the
raw data (5) and computational simulation results (solid line) from Model 3.
The fit of these models to the datasets is quite good since the general behaviour
seems to be mimicked by the model.
Data Average Model 1 Model 2 Model 3
HRN -
0.98239315 0.723754161 0.533049756
101.4413 83.39319 85.95446
Mouse 1 0.912719662 0.993406559 0.87235823 0.758075348
Mouse 2 0.476351664 0.848469337 0.334221281 0.224672664
Mouse 3 0.664126381 0.891435861 0.977396816 0.861637272
WT -
0.865898958 0.888208185 0.940834517
76.55137 68.72095 71.51396
Mouse 4 0.000410784 0.000207095 0.000388317 0.000376994
Mouse 5 0.000340973 0.000639792 0.000441549 0.000429731
Mouse 6 0.00035478 0.000404869 0.000293569 0.00031208
Table 3.18: Tamoxifen - Paired t Test p-values and AIC (Akaike’s Information Cri-
terion) values.
For all the wild type mice the average data has a significant p-value and
therefore the average difference is non-zero. This is not the case with the HRN
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data where the average is significantly similar for all the mice. The AIC values
suggest that the best model for the transgenic mice is the second model and this
is also the case in the wild type.
3.3.10 Thalidomide
For this drug the model parameters are:
Parameters WT HRN Ratio (3dp) S-W QQ Runs
Model 1
y(0) 7844.8679 14208.76 1:1.811
3 3 3
k10 0.3168 0.0975811 1:0.308
Model 2
y1(0) 11126.53 24408.25 1:2.194
3 3 3k12 3.907653 2.126012 1:0.544
k20 0.5605251 0.283173 1:0.505
Model 3
y1(0) 10938.48 35847.56 1:3.277
3 3 3
k12 4.024039 1.443215 1:0.359
k23 0.5415965 0.8693192 1:1.605
k32 0.03747103 0.5505027 1:14.691
a 103.8998 1006.862 1:9.691
Table 3.19: Thalidomide Model Parameters and outcomes at the 5% level from the
Normality Assumption tests (S-W = Shapiro-Wilks Test and QQ = Quartile-Quartile
Plot) and Runs Test.
For the Thalidomide data it is fine to assume normality in the residuals and
none of the models show systematic deviation from the data.
Model 1
The first model shows an increase in initial concentration from WT to HRN by
81.1%. This is coupled with a decrease in elimination rate with the value being
30.8% of the wild type flow.
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Figure 3.31: Plots showing the Thalidomide drug concentration against time for the
raw data (5) and computational simulation results (solid line) from Model 1.
The fit of this one compartment model to the average data is not good since
it does not include an absorption phase.
Model 2
For the second model the difference between the wild type and HRN model shows
an increase in the starting concentration by 2.194 times. The absorption and the
elimination parameters, k12 and k20, however, are smaller than the wild type at
54.4% and 50.5% of the value respectively.
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Figure 3.32: Plots showing the Thalidomide drug concentration against time for the
raw data (5) and computational simulation results (solid line) from Model 2.
The fit of this model to these data points is good but the peaks are not similar
in shape.
Model 3
For this model the starting value of HRN is 3.277 times bigger than the wild
type parameter. With the exception of k12 (35.9% the size) all the parameters
are larger in the HRN mouse - k23 is +60.5%, a is 9.691 times bigger and k32 is
14.691 times larger.
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Figure 3.33: Plots showing the Thalidomide drug concentration against time for the
raw data (5) and computational simulation results (solid line) from Model 3.
The visual fit of the model is good for the data although there is still a
disparity in peak shape for both mice.
Data Average Model 1 Model 2 Model 3
HRN -
0.980441293 0.917512018 0.922990225
142.0342 114.0037 111.3868
Mouse 1 0.0041872 0.187357181 0.003430427 0.00285762
Mouse 2 0.13911992 0.644791545 0.166101494 0.157164959
Mouse 3 0.00480581 0.553649658 0.032930053 0.01660397
WT -
0.851221037 0.857263377 0.95076315
125.982 100.7898 102.8101
Mouse 4 0.002257028 0.011975152 0.001897443 0.002564998
Mouse 5 0.001589166 0.059113262 0.002565842 0.001939229
Mouse 6 0.010637094 0.117544203 0.005813605 0.009099098
Table 3.20: Thalidomide - Paired t Test p-values and AIC (Akaike’s Information
Criterion) values.
All except mouse 2 show a significant result in the paired t test with the
average data suggesting that for these mice the average is not representative. As
such the agreement between the model fits and the real data is not good especially
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with respect to model 2 and 3. The AIC values suggest that the best model for
the HRN data is the third model and for the WT it is the second.
3.4 Discussion
When fitting the first model to the caffeine data the initial values were found to
be similar whereas the absorption rate was much slower in the HRN mouse than
in the WT. This is due to the absorption phase exhibited by the HRN data not
being a feature of a one compartment pharmacokinetic model.
For the second caffeine model there is a marked difference between the two param-
eter sets in the different mice. With both parameters the rates are much faster in
the wild type mouse than in the HRN. This suggests either that the transgenic
mouse has a slower metabolism than the wild type or the second model allows
too much complexity not exhibited by the wild type data leading to errors.
In the third model parameter sets there are rates that are set to zero. In the HRN
the k32 = 0 which means that any drug entering the third compartment cannot
leave. In the wild type it is a that is zero that means the excretion rate does
not change over time and since it is initially set to zero no excretion takes place.
Biologically speaking both these scenarios are unrealistic so the third model is
wrong for these data sets.
For both the HRN and wild type mice the third caffeine model has the better
visual fit for the data. However, when it comes to the AIC statistic deems model
1 as the best for the WT data and model 2 for the HRN data.
Due to its mechanism of action and enzyme metabolism it can be understood why
there might be a short or unmeasured absorption period. Since the injection is
into the peritoneum this causes the drug to be close to its metabolising enzymes
in the small intestine and liver.
With respect to the first Dextromethorphan model the fit is good for the wild
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type data but not for the HRN since it shows an absorption phase. The initial
values for the model are similar between the two mice although the elimination
rate is 50% slower in the HRN mouse. This could suggest a slower transport
through the gut in the transgenic mouse.
For the second model the fit is good for the both sets of data although in the
wild type mouse the fitted peak is jagged since there is no data supporting an
absorption phase. The initial concentrations are similar but the other two param-
eters are not. The absorption and elimination parameters for the HRN mouse are
0.8% and 60% of the size of the wild type parameter respectively. The absorption
parameter difference is explainable by the lack of data but the elimination being
less in the HRN than the WT concurs with model 1 which suggests evidence of
physical difference.
Even though the third model for both the mice shows good fit the k32 parameter
is zero for both datasets. This would mean there is a compartment in the model
which once entered can never be exited which is biologically unreasonable. Due
to this and the fact that the parameters show a large variation between the two
mice the model 3 is not a good model for this data.
As with the caffeine data the AIC statistic deems model 1 as the best for the WT
data and model 2 for the HRN data.
For both the wild type and HRN first Diclofenac models the parameters are very
similar in both mice. The fit of this model was good at the start of the time
period for both sets of the data.
In the second model the initial concentrations and excretion parameters are sim-
ilar between the wild type and HRN mice. The main difference between the two
models is in the absorption parameter where the HRN value is roughly 30% of
the wild type value. This calculated model shows a jagged fit due to the very
quick absorption and then the fit after the first hour is similar to that of model
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1. This could be due to a change in time scale dynamics i.e. fast to slow.
For the three-compartment model y(0), k23 and a show large differences between
the sets of data. The fit of the model is the best out of the three visually with
the only problem area being the shaping of the peak, which is jagged.
The AIC values suggest that the best model is model 3 for both sets of data,
which is consistent with the visual results.
For the first Gefitinib model there is a marked difference between the parame-
ters associated with the data sets. Both the initial concentration and excretion
rate are much lower (52.4% and 29.8% respectively) in the HRN mouse. The fit
however is good although both data sets show an absorption phase, which is not
included in this model.
In the second model the parameters all are lower in the HRN mouse (53.7% for
initial concentration, 72% for absorption and 31.6% for excretion) when compared
with the wild type mouse. The fit for this model is good for both the HRN and
wild type.
The model 3 parameters also showed differences between the HRN and WT fitted
parameters. Unlike the previous two models there is a parameter that is larger in
the HRN than the WT - k32. This fact indicates that compartment 3 in the HRN
mouse is less like a “fatty liver“ as was intended since it is easier to leave than
enter. All the other parameters are smaller in the HRN indicating an inherent
slower absorption and metabolism of this drug within the mouse.
The average data for Gefitinib in the mice show very different behaviour between
HRN and WT, which is visible from the multiple peaks in the HRN plot. Even
though it shows more difference from the models the HRN test statistics show
more similarity than all the WT model values.
The AIC values suggest that the best model for the HRN mouse is model 2
whereas for the WT this is the third model.
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With Imatinib there was uncertainty around the normality assumption for model
1 and 2 related to the HRN data. Due to the Quartile-Quartile plot showing
linearity it was still possible to use the non-linear least squares method to fit the
data for these models.
With the first Imatinib model both parameters are similar for the HRN and WT
data. The model only partially fit with the dynamics exhibited by the datasets
suggesting more complexity was needed.
For the second model the initial concentration and elimination were similar in
the two mice (difference of 10.1% and 1.5% respectively) whereas the absorption
rate was a third of the wild type rate in the HRN. This means that absorption
of this drug is much slower in this mouse. As with the previous model the fit is
partially good as the dynamics after the first two hours are not the same as the
data.
As with the second model the parameters in model 3 show little deviation between
the wild type and transgenic mouse. This is the case for all but the absorption
rate parameter, which has a very large difference. The model fit is good for both
sets of data. However in the wild type plot the peak is jagged suggesting too
quick a transition from absorption to elimination in the parameter set.
The AIC values suggested that the best model for the wild type data is the third
model and for the HRN this was also the case after the first model was ruled out
due to the normality assumption.
A more complex model may be needed to explain the metabolism since there are
five CYP enzymes associated. This might mean that there are different sites of
metabolism since they are located in both the hepatic system and small intes-
tine. As with the previous drugs this explains the very short absorption phase
exhibited by the data.
The one compartment Midazolam model with respect to this drug when fitted to
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the two sets of data showed marked differences in parameter values. The differ-
ences between them for the initial concentration and excretion were +52.8% and
41.2% (HRN compared to the WT) respectively. This means that the excretion
rate is much lower in the transgenic than in the wild type. The fit of this model
is fine although the data shows an absorption phase not fitted by the model.
For the second model the whole parameter set showed deviation between the two
data sets although with the exception of the initial concentration the values are
reduced in the HRN. The fit for this data is better in the HRN than the WT
although both models fail to mimic the behaviour after the one-hour point.
In the third model the initial concentration is once again larger in the HRN than
the WT with all other parameters being smaller. The absorption parameter is
nearly identical in both models suggesting that this is not a source of difference
between the mice. Out of the three models this one shows the best visual fit to
the data sets.
The AIC values showed that the HRN and wild type data were fitted best by the
model 2 and model 3 respectively. Through all three model fittings the parame-
ters for this drug were smaller with respect to the HRN mouse than the wild type
suggesting a physiological or metabolic difference. For both of the Midazolam
data sets model 3 is the best fit both visually and numerically. The fact that this
model fits well could be due to this drug being associated with only one CYP
enzyme located in the liver and small intestine.
For the first Omeprazole model there are large differences between the fitted pa-
rameter sets the HRN initial concentration is 1.5 times larger than the wild type
although the corresponding excretion rate is only 23.1%. As with other data sets
the HRN shows an absorption phase, which is not catered for within the one
compartment model. The wild type data model shows a good fit throughout the
time period.
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Although all of the Omeprazole models do not fit well when using the χ2 test
but out of all of them the third model shows the most similarity. This drug is
metabolised by two CYP enzymes that are located within the liver, which explains
the absorption phase being slower due to the movement from the peritoneum.
Within the second model there are large differences in the parameter values in-
cluding the initial concentration. This value is ten times higher in the transgenic
mouse and the excretion is 1.6 times larger but the absorption is only 6% of the
wild type value. These mean that the mouse has slow absorption and fast excre-
tion but starts out with a much higher amount of drug which is unusual since the
dose was the same in both mice. The fit to the data is good for both the wild
type and transgenic mice.
For the third model the parameter sets show large deviations as with the previous
two models especially in the initial concentration, which is double the wild type
value in the transgenic mouse. For the rate parameters, k12, k23 and k32 are 42.1%
smaller, 30.8% smaller and 1.585 times larger than the values in the wild type
respectively. The a parameter is also larger at roughly 4 times the WT value.
The “fatty liver“ compartment still holds for both sets of data as k23 >> k32.
The fit of this model is the best visually for both sets of data although the peaks
are jagged in shape.
The chosen models using the AIC values are the third model for the wild type
data and the second model for the HRN data.
For the first and third Paclitaxel model in the Hepatic Reductase Null mouse the
data shows significant systematic deviation from the fitted models. This agrees
with the fact that for both these models the line fits the data poorly in the HRN
mouse. As such the only model left for parameter comparison is the two compart-
ment model. The parameters in the second model show differences in the initial
concentration (+17%) and excretion rate (+4.6%) are larger in the transgenic
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mouse and the reverse is true for the absorption (0.2%). The AIC deems the
second model the best for the HRN and the third for the WT. This is congruent
with the visual fit of these models and the fact that the first and third models
are unsuitable for the HRN data due to the significant Runs test.
With regards to Tamoxifen the metabolism must be quite complex since it is an
oral administration and associated with six CYP enzymes. The data for this drug
go from 24 hours in the HRN and only for 7 for the WT. As such it is difficult
to compare fit between the two. There is a large gap between the 7 and 24-hour
point and as such fitting the models is difficult.
As with Paclitaxel, Tamoxifen HRN data shows systematic deviation but only in
regards to model 1. Since the Tamoxifen data shows an absorption phase this
model is not going to show the same behaviour.
For model 2 the initial concentrations between the two mice are similar whereas
the rate parameters representing absorption and excretion are smaller. The k12
parameter is 14.6% and the elimination is 62% of the wild type suggesting that
these processes are slower within the transgenic mouse. The fit of this model is
better for the WT data than that for the HRN data. There is disparity between
the HRN model and the raw data between the 7hr and 24hr points but this is
more due to a lack of points between.
In the third model the most worrying parameter difference is that the time depen-
dent elimination is zero in the wild type mouse i.e. dy4
dt
= 0 and since the initial
value for y4 is zero there is no excretion of this drug. The initial concentration in
the transgenic mouse is 65.1% higher than in the wild type but all the absorption
parameter is smaller so this phase is slower. The influx and outflow from the third
compartment are larger in the HRN than in the WT and this could indicate the
presence of a larger compartment or liver with a higher concentration of fat cells.
The AIC values suggest that the best model for the transgenic mice is the second
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model and this is also the case in the wild type. This means that the third com-
partment is not necessary for a good fit to the data. The data for both the wild
type and HRN mouse showed absorption and thus the first Thalidomide model
was not a good fit. Although the initial concentration for the second model was
roughly double in the HRN mouse the rate parameters associated were both half
the wild type rate. This suggests that physiologically the absorption and elimina-
tion of the transgenic mouse was much slower than a normal mouse metabolising
Thalidomide. The visual fit of this model to the data sets was good with the
exception of the peak area.
For the third model there was large differences in the parameter values with all
being greater in the HRN with the exception of k12 which was a third of the WT
rate. The visual fit of the model is good for the data although there is still a
disparity in peak shape for both mice.
The AIC values suggest that the best model for the HRN data is the third model
and for the WT it is the second. This drug is only associated with one CYP
enzyme in the liver which should mean a less complex model is best which is the
case in the wild type mouse.
Throughout this chapter the same three models have been fitted to the data sets
with varying amount of success. The reasons for this varied from the need of
an absorption phase i.e. model 1 is unsuitable to more peaks exhibited by the
data than are allowed in the model formulation. It shows that although the tra-
ditional one compartment (model 1) and two compartment (model 2) fit well to
the data sometimes a more complex model is necessary. The complex behaviour
could stem from the need for multiple time scales this could mean multiple Cy-
tochrome P450 enzymes are acting on the drug. The novel model 3 outlined in
this chapter takes a step towards addressing this need for more complexity.
When the parameters for the HRN and wild type mice were compared for most
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of the data sets the HRN rates were slower than their counterpart. This could
mean there is a metabolic difference between the two mice stemming from the
genetic knockout. Since metabolism is dependent on a number of factors it is
difficult to pin this down to one physiological parameter. Within the Tamoxifen
model 3 there was evidence supporting the observation that the knockout caused
a liver filled with a higher proportion of lipid cells.
The problem with fitting the compartment models to these sets of data is gener-
ated by experimental constraints. It would be easier if more data were available
instead of just three mice of each type for each drug. This would mean that the
average would be statistically more representative which would aid in providing
a better fit.
Other than the number of mice it would be useful if more samples could be taken
or at least they could be more regular. However this is unfeasible since the vol-
ume of blood in a mouse is finite and takes a while to replenish. It is due to these
constraints that sampling is prioritised within the first hour after the dose. For
some of the drugs shown in this chapter earlier sampling is needed in order to
record concentrations during fast processes such as absorption e.g. Caffeine.
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Chapter 4
Sensitivity Analysis
4.1 Introduction
Sensitivity analysis is a method of investigating the effect of parameter change
on the solution of models (Turanyi, 1990) that can be anything from kinetic to
stochastic models in science and engineering (Varma et al., 1999). This is useful
for optimising the parameters in order to fit real data or finding out if there are
any parameters that have little or no effect so they can be left out of the next
formulation of the model. Also to analyse the robustness of the model to errors
in parameter estimation and experimental error.
There are numerous ways of getting sensitivity measures including local and
global techniques. Local methods produce gradients with relation to the param-
eter at time points along the domain. When looking for the global sensitivity it
finds parametric importance over the parameter space in question (Rabitz et al.,
1983).
Examples of local sensitivity methods are (Rabitz et al., 1983; Turanyi, 1990)-
Finite difference methods, Curve fitting and derivative extraction, Direct differ-
ential methods, Green‘s Function Method (GFM) and Analytically Integrated
Magnus (AIM method. The first three in this list give accurate sensitivities (to
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different degrees) and have a low computational cost. When the number of pa-
rameters gets large in comparison to the number of variables, then the GFM or
AIM are advised (Turanyi, 1990) to get the sensitivity gradient.
Global techniques for sensitivity analysis are - Stochastic Sensitivity Analysis,
Fourier Amplitude Sensitivity Test (FAST), Walsh Amplitude Sensitivity Proce-
dure (WASP), Monte Carlo and Latin hypercube methods. Global methods are
more computationally intensive and therefore it is more difficult to attain these
sensitivities. As such local measures are used more often in the literature due to
these constraints.
Some of these techniques (either local or global) are more popular in the liter-
ature than others, for example, FAST and Monte Carlo methods are popular
global techniques, whereas, for the local methods finite difference is most often
used. Some good reviews of these methods can be found in Rabitz et al. (1983),
Kramer and Leis (1988), Turanyi (1990) and Saltelli et al. (2005).
4.2 Sensitivity Analysis Theory
4.2.1 Sensitivity Coefficients
Local Techniques
Finite difference methods are sometimes thought of as a brute force or indirect
method and the application of this is using the following equation (Turanyi, 1990):
∂c(t2)
∂kj(t1)
' c(t2, kj + ∆kj)− c(t2, kj)
∆kj
,
with reference to the differential equation:
dc
dt
= f(c, k).
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This method is used frequently since a normal ODE solver is the only code needed
to solve for the sensitivity coefficients.
Takors et al. (2004) used the finite difference method to simplify complex kinetic
models explaining metabolic pathways concerning glycolysis in E. Coli. This
model started out with 122 parameters and using sensitivity analysis they were
able to minimise this number to 73 parameters.
Zak et al. (2005) used this method while investigating models explaining cell
cycle and circadian dynamics. Since these models deal with situations that show
oscillations, it is more difficult to tell whether the sensitivity is to do with the
behaviour of the system or parameter changes.
For biophysical models, Gunawan et al. (2005) compared deterministic (finite
difference method) and stochastic (Monte Carlo) approaches to calculating the
sensitivity coefficients.
Global Techniques
Saltelli et al. (2005) compare the results from local (Taylor expansion) and global
methods (FAST, Monte Carlo and Latin Hypercube sampling). It uses theoretical
chemical reactions in order to investigate issues with computer use and outcome
quality. These were calculated on SIMLAB and therefore it is easier to compare
computational cost.
In Gertner and Xu (2008) the FAST method is investigated through a number of
test cases and is compared to an ANOVA (ANalysis Of VAriance) method. One
of the main uses for the FAST method in this paper was to account for correlated
and uncorrelated parameters.
Monte Carlo methods include Markov Chain Monte Carlo (MCMC) that can be
seen in Jayawardhana et al. (2008) and Calvetti et al. (2008). In the Jayaward-
hana et al. (2008) paper MCMC is used in conjunction with Bayesian inference
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to investigate parametric estimation in glycolytic and pyruvate pathways. This
paper shows a method that uses steady state data and copes with outside factors
that affect the variables but are not present in the equations. Calvetti‘s paper
also uses a Bayesian framework to analyse dynamic compartment based models
dealing with myocardial metabolism. Due to the size of the model it draws some
conclusions about the pathway but ends pretty inconclusively.
Ancheyta and Alca´zar (2007) use Monte Carlo methods for parameter estimation
as does Kramer and Snowling (2001) and Horenko et al. (2005). They all use the
Monte Carlo method to pick estimates from a probability density function and
simulate the model through time to see how change in parameters changes the
model solution.
4.2.2 Analysis of the Difference between the Percentile
and Normal Drug Uptake Curves
In order to test the effects caused by altering parameters it is necessary to choose
how big a change is required to obtain a significant change. In the current liter-
ature there are large differences in the size of change ranging from 1% to 50%.
Some have worked with a 1% change either side of the chosen parameter value
Yang et al. (1997), Rieger et al. (2005), Gunawan et al. (2005) and Zak et al.
(2005). There are examples of larger differences showing a 10% change - Ancheyta
and Alca´zar (2007), Gertner and Xu (2007), Brugnach (2005) and Gertner and
Xu (2008). Finally Ancheyta and Alca´zar (2007) and Saltelli et al. (2005) show
that up to a 20% change is feasible and for second order derivatives a 50% change
holds (Saltelli et al., 2005).
93
4.3 Sensitivity Analysis Method
4.3.1 Sensitivity Test
Using sens sys.m developed by Molla´ and Padilla (2002) for MATLAB as a re-
placement for ODE15s as its base the sensitivity coefficients dy
du
were calculated
where y is the variable and u is the parameter. This function requires a system
of vectorised equations, initial and parameter values in order to calculate the
derivative over time with respect to the parameter. Sens sys.m uses an iterative
approximation in order to find the derivatives (Molla´ and Padilla, 2002).
Once the sensitivity coefficients have been found it is useful to plot them over
time and examine their effect on the variable, which can be either: positive, neg-
ative, both and none. As well as this inspection a look at the maximum and
minimum value and therefore the range helps to find the parameters that have
the most effect on the variable in question.
In the previous chapter where compartment models were applied to the CXR Bio-
sciences data sets the model parameters showed both small and large differences
between the HRN and wild type mice. The smallest deviation for the Midazolam
data used in this chapter was 4.4% and the largest was 77.6%. Due to this and
from the evidence outlined in the previous section a 10% deviation was chosen as
a big enough change to ensure response is significant for the sensitivity test.
4.3.2 Magnitude Measure
The magnitude measure is the following test statistic:
∑ (ynorm±10% − ynorm)2
(pnorm±10% − pnorm)
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It can be seen that this equation is based on a least-squared approach, since if
there is little difference between the curves this value will be small. The denom-
inator compensates for the magnitude of the 10% difference to allow comparison
between parameters.
Once this sum has been calculated the maximum is found. As it is possible that
many parameters could have a similar strength of sensitivity the parameters that
have a similar effect in size are included. This is achieved by tabulating all the
parameters with a result within the following range:
[10−3
∑ (ynorm±10% − ynorm)2
(pnorm±10% − pnorm) , 10
3
∑ (ynorm±10% − ynorm)2
(pnorm±10% − pnorm) ] (4.1)
As well as this measure a paired t test was used to analyse the differences between
the data sets as explained in section 3.3.
4.3.3 Extended Sensitivity Testing
Using a random number from a gamma distribution dependent on the mean
and variance being the original value and +/- 10% respectively. The gamma
distribution was chosen due to it being characterised as wholly positive and only
bound at zero. The mean and variance for this distribution are defined as:
x¯ =
α
λ
σ2 =
α
λ2
(4.2)
Using these equations the correct parameter for the distribution associated with
the original model parameter values. Rearranging and solving simultaneously the
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above equations using a variance of 10%-(-10%) = 20% the equations become:
α = λx¯ = 0.2λ2 (4.3)
⇒ λ = 5x¯ (4.4)
⇒ α = 5x¯2 (4.5)
After the distribution parameters are found as above the model is run with one
hundred random values from the appropriate distribution. At each time point the
minimum and maximum value was taken and from these a range is calculated.
4.4 Results
For the first three models the parameter values are taken from the fitted mod-
els to Midazolam (Wild Type) data as shown in table 3.11. For Cytochrome
P450 (CYP) cycle and model the initial values of enzyme and drug are 3 and 5
respectively and the parameters are shown in Tables 5.3 and 5.4.
4.4.1 Model 1
This model has the following equation and initial value:
dy
dt
= −k10y
When changing the parameter k10 by 10% the graph of the function and the
associated sensitivity graph for y shows:
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Figure 4.1: The left hand plot shows the difference between the fitted model in compar-
ison with a 10% difference in Model 1 with the k10 parameter over time. The right hand
plot shows the calculated sensitivity from sens sys.m for the parameter and variable over
time.
It can be observed that the parameter has a large effect at around the one-hour
point. This is consistent with the ten percent graph above as the only difference
shown is initiated around this time point. The fact that the sensitivity graph is
negative means that as the parameter value gets larger the variable should be
smaller. This is also shown in the ten percent plot, as the “110% k10“ line is
smaller than the “norm“ line, which is less than the “90% k10“line.
The results of the magnitude and paired t test p values are:
Model1 k10
Σ
110% 3858.10121
90% 2857.983479
t
110% 2.14899E-16
90% 2.12118E-14
Table 4.1: Model 1 - t Test p values and Magnitude Test Statistics.
As the p values for the paired t test are much less than 0.05 the null hypothesis
is rejected in favour the alternative that is the value of y is independent of the
change in parameter k10. The magnitude result is large but this is expected since it
is the only parameter. The parameter k10 has an associated gamma distribution of
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Γ(4.6986818,4.847). The maximum range from the extended sensitivity analysis
is 78.58821432 for k10. The different curves are shown in the following plot:
Figure 4.2: Plot showing the impact of using a random value from a probability density
function for the parameter k10 in Model 1.
It can be observed from this that the change in parameter value can make a
large difference, which confirms the results from the previous tests.
4.4.2 Model 2
The equations for this model are:
dy1
dt
= −k12y1 (4.6)
dy2
dt
= k12y1 − k20y2 (4.7)
The explicit solutions to this system of equation show that the following relation-
ship between the variables and parameters should hold:
Model2 k12 k20
y1 3 7
y2 3 3
Table 4.2: Model 2 Explicit Solution Relationship with Parametric Sensitivity.
The three ten percent graphs (since y1 and k20 show no sensitivity as shown
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in the table above) associated with the change in parameter value for both k12
and k20 are:
Figure 4.3: The left hand plot shows the difference between the fitted model in com-
parison with a 10% difference in Model 2 with the k12 parameter with respect to y1
over time. The right hand plot shows the calculated sensitivity from sens sys.m for the
parameter and variable over time.
This plot shows sensitivity in the first hour and is negative, therefore the
larger the parameter value is for k12 the smaller y1 should be and the ten percent
plot shows this.
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Figure 4.4: The left hand plot shows the difference between the fitted model in com-
parison with a 10% difference in Model 2 with the k12 parameter with respect to y2
over time. The right hand plot shows the calculated sensitivity from sens sys.m for the
parameter and variable over time.
These plots show that y2 is sensitive to k12 for the first 3 hours. The first 0.5
hour the graph shows a positive sensitivity which means that the larger k12 is,
the larger y2 is, but then after this point y2 is negatively sensitive to k12 i.e. the
larger k12 causes a smaller y2 value.
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Figure 4.5: The left hand plot shows the difference between the fitted model in com-
parison with a 10% difference in Model 2 with the k20 parameter with respect to y2
over time. The right hand plot shows the calculated sensitivity from sens sys.m for the
parameter and variable over time.
This plot shows sensitivity over the entire time period and is negative so that
the larger the parameter value is for k20 the smaller y2 should be and the ten
percent plot shows this.
The results for the magnitude are:
Model2 k12 k20
y1
110% 46.42571648 4.10729E-11
90% 63.43745506 3.97125E-11
y2
110% 34.60459351 1921.869627
90% 46.15739087 2604.567308
Table 4.3: Model 2 - Σ Test Statistics.
And for the paired t test:
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Model2 k12 k20
y1
110% 0.999999616 0.042932943
90% 0.034748543 0.039667563
y2
110% 0.870438539 1.22367E-09
90% 0.886952553 8.39084E-11
Table 4.4: Model 2 - Paired t Test p values.
In order to find out the most effective parameter for each y it is useful to
look at the magnitude and t test jointly. For y1 and y2, k12 and k20 are the most
effective parameters respectively.
The extended sensitivity analysis showed parameter distribution and maximum
ranges as follows:
Model2 k12 k20
p.d.f Γ(385.2225313, 43.8875) Γ(9.47100845, 6.8815)
y1 13.29368206 1.78471E-05
y2 12.11069991 74.79936767
Table 4.5: The ranges and Probability Density Functions with respect to the parameters
and variables for Model 2.
The effect of the change of values k12 on y1 is shown in the following plot:
Figure 4.6: Plot showing the impact of using a random value from a probability density
function for the parameter k12 with respect to y1 in Model 2.
From this plot and the range value in the table shows that k12 has an effect
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on the value of y1 over the first hour. For y2 the parameter k12 has less of an
effect shown by the range values and the plot is:
Figure 4.7: Plot showing the impact of using a random value from a probability density
function for the parameter k12 with respect to y2 in Model 2.
Both variables are affected by k12 to a similar extent and over the first three
hours. This confirms the results from the t test p values and the magnitude test
statistics. For k20, from all previous tests, shows that it has a large effect on y2
and the plot is:
Figure 4.8: Plot showing the impact of using a random value from a probability density
function for the parameter k20 with respect to y2 in Model 2.
This shows a wide range in resultant curves for y2 at least beyond the 0.5-hour
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point.
4.4.3 Model 3
The equations for this model are:
dy1
dt
= −k12y1 (4.8)
dy2
dt
= k12y1 − k23y2 + k32y3 − y4 (4.9)
dy3
dt
= k23y2 − k32y3 (4.10)
dy4
dt
= a (4.11)
The explicit solutions to this system of equation show that the following relation-
ship between the variables and parameters should hold:
Model3 k12 k23 k32 a
y1 3 7 7 7
y2 3 3 3 3
y3 3 3 3 3
y4 7 7 7 3
Table 4.6: Model 3 Explicit Solution Relationship with Parametric Sensitivity.
The ten percent graphs for this model are (again if the table above shows no
sensitivity the plot is not shown):
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Figure 4.9: The left hand plot shows the difference between the fitted model in com-
parison with a 10% difference in Model 3 with the k12 parameter with respect to y1
over time. The right hand plot shows the calculated sensitivity from sens sys.m for the
parameter and variable over time.
It is unclear from the ten percent plot, which way the parameter difference
affects the y1 value but from the sensitivity graph it shows that as k12 increases
y1 decreases, but the sensitivity is only prevalent in the first hour.
Figure 4.10: The left hand plot shows the difference between the fitted model in com-
parison with a 10% difference in Model 3 with the k12 parameter with respect to y2
over time. The right hand plot shows the calculated sensitivity from sens sys.m for the
parameter and variable over time.
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At the start of the time period the effect of k12 on y2 is positive and then
after 0.5 hours the sensitivity curve becomes negative. After the 3-hour point the
variable is no longer sensitive to the parameter change.
Figure 4.11: The left hand plot shows the difference between the fitted model in com-
parison with a 10% difference in Model 3 with the k12 parameter with respect to y3
over time. The right hand plot shows the calculated sensitivity from sens sys.m for the
parameter and variable over time.
Within the first two hours the “norm +10%“ curve will be bigger than the
norm due to a positive sensitivity but this lessens by the 2hr point.
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Figure 4.12: The left hand plot shows the difference between the fitted model in com-
parison with a 10% difference in Model 3 with the k23 parameter with respect to y2
over time. The right hand plot shows the calculated sensitivity from sens sys.m for the
parameter and variable over time.
The sensitivity plot shows a negative effect of the parameter k23 on y2, which
means that if k23 is bigger than the norm of the model it causes y2 to be smaller
than the norm curve.
Figure 4.13: The left hand plot shows the difference between the fitted model in com-
parison with a 10% difference in Model 3 with the k23 parameter with respect to y3
over time. The right hand plot shows the calculated sensitivity from sens sys.m for the
parameter and variable over time.
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k23 has a positive effect on y3 over the entire period which means that if k23
is larger then y3 will be larger too.
Figure 4.14: The left hand plot shows the difference between the fitted model in com-
parison with a 10% difference in Model 3 with the k32 parameter with respect to y2
over time. The right hand plot shows the calculated sensitivity from sens sys.m for the
parameter and variable over time.
k32 has a positive effect on y2 over the entire period which means that if k32
is larger then y2 will be larger too.
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Figure 4.15: The left hand plot shows the difference between the fitted model in com-
parison with a 10% difference in Model 3 with the k32 parameter with respect to y3
over time. The right hand plot shows the calculated sensitivity from sens sys.m for the
parameter and variable over time.
k32 has a positive effect on y3 over the entire period which means that if k32
increases, y3 will do the same.
Figure 4.16: The left hand plot shows the difference between the fitted model in com-
parison with a 10% difference in Model 3 with the a parameter with respect to y2 over
time. The right hand plot shows the calculated sensitivity from sens sys.m for the pa-
rameter and variable over time.
The sensitivity plot shows a negative effect of the parameter a on y2 which
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means that if a is bigger than the norm of the model it causes y2 to be smaller
than the norm curve especially at the end of the period since that is when the
sensitivity is higher.
Figure 4.17: The left hand plot shows the difference between the fitted model in com-
parison with a 10% difference in Model 3 with the a parameter with respect to y3 over
time. The right hand plot shows the calculated sensitivity from sens sys.m for the pa-
rameter and variable over time.
The sensitivity plot shows a negative effect of the parameter a on y3. This is
similar to the effect a has on y2.
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Figure 4.18: The left hand plot shows the difference between the fitted model in com-
parison with a 10% difference in Model 3 with the a parameter with respect to y4 over
time. The right hand plot shows the calculated sensitivity from sens sys.m for the pa-
rameter and variable over time.
The parameter a has a positive effect on y4 over the entire period which means
that if a is larger then y4 will be larger too this is understandable since it is di-
rectly proportional to the gradient in the model equations.
The magnitude results are:
Model3 k12 k23 k32 a
y1
110% 142.0500983 1.03102E-11 1.66127E-12 1.81789E-16
90% 192.5731239 1.92793E-11 1.59893E-12 4.75816E-17
y2
110% 77.85633289 1358.358575 3093.936724 73.76749612
90% 100.3570105 1848.135197 3196.142832 73.7674949
y3
110% 53.87347289 1358.353019 3093.938887 771.0636614
90% 77.44943342 1848.128794 3196.145423 771.0636694
y4
110% 3.97087E-27 3.40951E-27 7.77754E-26 239.498688
90% 1.46177E-27 5.77218E-27 8.26689E-26 239.498688
Table 4.7: Model 3 - Σ Test Statistics.
And the paired t test p values are:
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Model3 k12 k23 k32 a
y1
110% 0.015781416 0.676968011 0.262424501 0.003326071
90% 0.010518866 0.34072817 0.449552078 0.000741898
y2
110% 0.867849815 1.40703E-11 2.66665E-30 2.84028E-15
90% 0.840208799 1.95825E-12 3.13127E-30 2.84028E-15
y3
110% 0.000115989 1.40715E-11 2.66663E-30 4.20416E-11
90% 8.15396E-05 1.95843E-12 3.13125E-30 4.20415E-11
y4
110% 6.03094E-06 0.705790135 0.004538659 2.13912E-19
90% 0.717919965 0.084834393 2.48321E-05 2.13912E-19
Table 4.8: Model 3 - Paired t Test p values.
Most of the paired t test p values in the table are significant at the 5% level
with the exception of k23:y1, k23:y4 and k12:y4(90%). Due to this it is better to
draw conclusions from both statistics jointly. y2 by k32; y3 by k32 and y4 by a in
both result sets. For y1, the magnitude results show that it is primarily affected
by k12. However the paired t test suggests that a is the most significant which
is odd since the explicit solution for y1 does not contain a. From the magnitude
results it can be seen that k23 also has an effect on y2 and y3 but not as great as
k32.
For the extended sensitivity analysis the probability densities and ranges are as
follows:
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Model3 k12 k23
p.d.f Γ(199.0805,31.55) Γ(21.9828512,10.484)
y1 18.16077958 6.95738E-06
y2 15.3054356 49.30430778
y3 7.9238265 49.30425246
y4 4.9738E-14 4.9738E-14
Model3 k32 a
p.d.f Γ(0.19424205,0.9855) Γ(52.6436352,16.224)
y1 1.90479E-05 2.35617E-08
y2 88.17826511 9.226851326
y3 88.17827273 34.89966143
y4 9.9476E-14 14.70883874
Table 4.9: The ranges and Probability Density Functions with respect to the parameters
and variables for Model 3.
For k12 the variable y1 is sensitive just as the following plot shows:
Figure 4.19: Plot showing the impact of using a random value from a probability
density function for the parameter k12 with respect to y1 in Model 3.
However the sensitivity is only in effect for the first two hours as was shown
on the ten percent plot. y2‘s reaction to change in the parameter k12 is shown as
follows:
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Figure 4.20: Plot showing the impact of using a random value from a probability
density function for the parameter k12 with respect to y2 in Model 3.
From this plot that the sensitivity is slightly larger than the previous plot
occurs across the entire time period. For y3 the extended sensitivity plot is:
Figure 4.21: Plot showing the impact of using a random value from a probability
density function for the parameter k12 with respect to y3 in Model 3.
This plot shows a low sensitivity but looks very similar in banding to the last
plot.
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Figure 4.22: Plot showing the impact of using a random value from a probability
density function for the parameter k23 with respect to y2 in Model 3.
The parameter k23 effect on y2 shown above, indicates the large sensitivity;
which is in line with the other tests of sensitivity.
Figure 4.23: Plot showing the impact of using a random value from a probability
density function for the parameter k23 with respect to y3 in Model 3.
The interaction between k23 and y3 is similar in range size and magnitude
statistic as that of y2.
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Figure 4.24: Plot showing the impact of using a random value from a probability
density function for the parameter k32 with respect to y2 in Model 3.
The above plot shows the effect of change in k32 value on y2 in the model.
This shows that this parameter can be the difference in the curviness of the profile
after the 0.5-hour point.
Figure 4.25: Plot showing the impact of using a random value from a probability
density function for the parameter k32 with respect to y3 in Model 3.
As with k23 the effect on y2 and y3 is very similar in magnitude. However in
the case for k32 the reaction is larger for y3 than for y2.
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Figure 4.26: Plot showing the impact of using a random value from a probability
density function for the parameter a with respect to y2 in Model 3.
The parameter a causes differences in the profile after the two hour point.
Although this parameter has an effect on the variable y2 it is not the largest
range over the variables.
Figure 4.27: Plot showing the impact of using a random value from a probability
density function for the parameter a with respect to y3 in Model 3.
For the variable y3 the parameter a has a similar effect in size to y2 and the
location of the difference is the same for both variables.
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Figure 4.28: Plot showing the impact of using a random value from a probability
density function for the parameter a with respect to y4 in Model 3.
As can be seen from the equations for this model the parameter a should have
the most effect on y4. A summary of the test results are shown in the following
table:
Variable Magnitude Parameters t test Maximum Range
y1 k12 a k12
y2 k12, k23, k32, a k32 k32
y3 k12, k23, k32, a k32 k32
y4 a a a
Table 4.10: The most prominent parameters for the Model 3.
The table above shows that the extended sensitivity analysis, paired t test
and magnitude tests all show similar answers for y4. For y1 the tests show a
dependence on the parameter a where due to the explicit solution there should
be very little effect.
4.4.4 Cytochrome P450 Cycle
This cycle relates to the equilibria outlined in section 1.4 and is used within the
cellular automata model in Chapter 5. Please refer to these sections for greater
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detail of the model assumptions. The model equations are:
d[E]
dt
= k−1[ES] + k7[EP ] + k8[GSO2] + k9[HSO]− (k1 + k−7)[E] (4.12)
d[S]
dt
= k−1[ES] + k8[GSO2] + k9[HSO]− k1[S] (4.13)
d[ES]
dt
= k1[E][S]− (k−1 + k2)[ES] (4.14)
d[FS]
dt
= k2[ES] + k−3[FSO2]− k3[FS] (4.15)
d[FSO2]
dt
= k3[FS][O2]− (k−3 + k4)[FSO2] (4.16)
d[GSO2]
dt
= k4[FSO2]− (k5 + k8)[GSO2] (4.17)
d[HSO]
dt
= k5[GSO2]− (k6 + k9)[HSO] (4.18)
d[EP ]
dt
= k6[HSO] + k−7[E][P ]− k7[EP ] (4.19)
d[P ]
dt
= k7[EP ]− k−7[P ] (4.20)
The parameter values used for this model are as outlined in table 5.4.The ranges
of sensitivity for this model for each parameter with relation to the variables are:
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The [E] concentration is mostly affected by k2, k3 and k8. However, all other
parameters show sensitivity for this variable to a lesser extent. The parameters
with a positive effect (i.e. the larger the parameter the larger the variable‘s value)
are: k3 and k4. The parameters with a negative effect are k−1, k1, k−3 and k−7.
All other parameters have both a positive and negative effect.
The concentration of [S] is primarily affected by the same parameters as [E] as
well as k5, k6 and k9. The sensitivities for k−1 to k4, k7 and k−7 all have both
positive and negative effect, k5 and k9 have positive sensitivity whereas k6 and
k8 have a negative effect.
The primary parameters for [ES] are k−1 and k2. All the sensitivities for this
variable are ones with a positive and negative effect over the time period.
The variable [FS] is primarily affected by k2 and k3. The parameters with a pos-
itive effect are: k−1, k1, k3, k4 and k−7. The parameters with a negative effect
are: k2 and k−3. All others have a positive and negative effect.
The [FSO2] concentration is primarily affected by k2 and k4. The split of positive
and negative sensitivities are the same for this variable as with the last with the
exception of k−3 and k3 which are the reverse i.e. k−3 has a negative effect and
k3 a positive one.
Variable [GSO2] is highly sensitive to k3, k5 and k8. The parameters with a nega-
tive effect are: k−1, k1, k−3, k5, k−7 and k8. The parameters with a positive effect
are: k2, k3 and k4. All others have a positive and negative effect.
The [HSO] concentration is primarily affected by k3, k5, k6, k8 and k9. All the
sensitivities are similar in effect as [GSO2] with the exception of k5, k6 and k9 k5
has a positive effect rather than negative, k6 has a negative rather than both and
k9 has a straight negative effect rather than varying from positive and negative.
The enzyme-product complex [EP] is primarily affected by k3, k6, k8 and k9. The
parameters have a similar effect on this variable as it did with the last with the
122
exception of k6 and k7. For k6 the variable is positively sensitive and k7 has
negative sensitivity rather than both positive and negative.
The product concentration [P] is affected by k2, k4, k5, k−7 and k9. The sensitiv-
ities are comparable to the [EP] effects but k7 has both a negative and positive
effect rather than just negative.
The magnitude, paired t test and extended sensitivity results are:
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Variable Magnitude Parameters t-test Maximum Range
[E] k−1, k2, k3, k4 k3 k3
[S]
k−1, k1 (90%), k2, k3, k8 k3
k4, k5, k6, k8, k9
[ES]
k−1, k2, k3, k5 (110%), k5 (110%)
k−1k6 (110%), k8 (110%), k9 (110%) k4 (90%)
[FS] k−1, k1 (90%), k2, k3, k4 k−7 k3
[FSO2] k2, k3
k−7 (110%)
k3k−1 (90%)
[GSO2] k2, k3, k4, k5, k8 k4 k3
[HSO] k2, k3, k4, k5, k6, k8, k9 k5 k3
[EP] k2, k3, k4, k5, k6, k7 (110%), k8, k9 k5 k3
[P] k2, k3, k4, k5, k6, k−7, k8, k9 k5 k3
Table 4.18: The most prominent parameters for the CYP Cycle.
The magnitude table shows that the most prominent parameters are as shown
in the table. It can be seen from this table that there is coherence between the
prominent parameters mostly that k3 affects the most variables.
4.4.5 Cytochrome P450 Model
This model is used within the cellular automata outlined in Chapter 5 specifi-
cally in section 5.2.2. Please refer to this section for greater detail of the model
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assumptions. The parameters are shown in table 5.4. The model equations are:
dy1
dt
= −k12y1 (4.21)
dy2
dt
= k32[S] + k12y1 − k23y2 − y3 (4.22)
dy3
dt
= a (4.23)
d[E]
dt
= k−1[ES] + k7[EP ] + k8[GSO2] + k9[HSO]− (k1 + k−7)[E] (4.24)
d[S]
dt
= k23y2 + k−1[ES] + k8[GSO2] + k9[HSO]− (k1 + k32)[S] (4.25)
d[ES]
dt
= k1[E][S]− (k−1 + k2)[ES] (4.26)
d[FS]
dt
= k2[ES] + k−3[FSO2]− k3[FS] (4.27)
d[FSO2]
dt
= k3[FS][O2]− (k−3 + k4)[FSO2] (4.28)
d[GSO2]
dt
= k4[FSO2]− (k5 + k8)[GSO2] (4.29)
d[HSO]
dt
= k5[GSO2]− (k6 + k9)[HSO] (4.30)
d[EP ]
dt
= k6[HSO] + k−7[E][P ]− k7[EP ] (4.31)
d[P ]
dt
= k7[EP ]− k−7[P ] (4.32)
The parameter values used as a basis for the sensitivity analysis are outlined in
Table 5.4. The sensitivity for the variables can be summarised in the following
table:
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Variable Primarily affected Positive Negative Both None
y1 k12 - k12 - All but k12
y2 k12, k23 , k32, a k1 a, k7 and k8 all other -
y3 a a - - All but a
[E] all but a, k1 and k−3
k12, k23
k32, a and k1 all other -and k2
[S]
k12, k23 , k32,
- a and k7 all other -a and k−1
[ES] all but k−3 and k−7 - - all other -
[FS]
k12, k23, k−1, k2,
- a all other -
k−3, k3, k4 and k7
[FSO2]
k12, k23, k32, k−1,
- a all other -
k2, k3, k4 and k7
[GSO2]
k12, k23, k32, k−1, k12, k23 k32, a, k−1, k1,
all other -
k2, k3, k4, k5 and k7 and k2 k5, k7 and k8
[HSO]
k12, k23, k32, k−1, k2, k12, k23 k32, a, k−1, k1,
all other -
k3, k4, k5, k6 and k7 and k2 k6, k7, k8 and k9
[EP] all but a, k1 and k−3
k12, k23 k32, a, k−1, k1,
all other -
and k2 k−7, k7, k8 and k9
[P] all but a, k1 and k−3
k12, k23 k32, a, k−1, k1,
all other -
and k2 k7, k8 and k9
Table 4.19: The most prominent parameters in the CYP model according to the dydu
statistic.
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When a parameter has a “Both“ effect on the variable it means that there
are both positive and negative effects from the parameter during the time pe-
riod. This could mean that the plots show cycling, or it only has a small posi-
tive/negative effect for part of the time period and then it crosses the t-axis to
cause a negative/positive effect. The extended sensitivity ranges and probability
density functions are as follows:
Parameter p.d.f Parameter p.d.f
k12 Γ(320,80) k23 Γ(5,10)
k32 Γ(0.2,2) a Γ(1.8,6)
k−1 Γ(200000,2000) k1 Γ(80000000,40000)
k2 Γ(2722.37778,233.34) k−3 Γ(200000,2000)
k3 Γ(0.2,2) k4 Γ(2722.37778,233.34)
k5 Γ(67.19778,36.66) k6 Γ(6.05,11)
k−7 Γ(2420,220) k7 Γ(200000,2000)
k8 Γ(13.87778,16.66) k9 Γ(13.87778,16.66)
Table 4.24: The Probability Density Functions with respect to the parameters for the
CYP Model.
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Variable Magnitude Parameters t test Maximum Range
y1 k12 k12 k12
y2 k12, k23, a k6 a
y3 a a a
[E] k12, k23, k−1, k7, k8 (90%) a k23
[S] k12, k23, a, k−1 a a
[ES]
k12, k23 (90%),
a k23k−1 (110%), k7 (110%)
[FS]
k12, k23, k−1, k2 (90%), k−3 (90%),
a k3k3 (110%), k4 (110%), k7 (110%)
[FSO2]
k12, k23, k−1, k2,
k6 k23k−3 (90%), k4, k7
[GSO2]
k12, k23, k−1, k2, k8 (110%)
k23k4, k5, k7, k8 k5 (90%)
[HSO]
k12, k23, k−1, k2, k6 (110%)
k23k5, k6, k7, k8, k9 k9 (90%)
[EP]
k12, k23, k−1, k2, k5,
k9 k23k6, k−7, k7, k8, k9
[P]
k12, k23, k−1, k2,
k9 k23k5, k6, k−7 (90%), k7, k8, k9
Table 4.26: The most prominent parameters for the CYP model.
The three tests seem to concur over the parameter with the highest sensitivity
for the variable.
4.5 Discussion
For model 1 it is understandable that within a ‘one variable - one parameter sys-
tem that this would have an effect, so this was to test if the methodology worked
correctly.
In model 2 there are two parameters and variables and the tests concurred with
the plots. This means that the parameters with the most effect k12:y1 and k20:y2.
The extended sensitivity analysis also shows this conclusion is valid. It is under-
standable that these parameters have the biggest effect on the variable since they
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are the excretion/removal rate for the compartment in question.
The third model has four variables and parameters and the parameters that have
the most effect are k12:y1, k32:y2, k32:y3 and a:y4. It is surprising that the pa-
rameter a has less effect on y2 than others considering affects the main excretion
out of this compartment.
The y3 is supposed to represent a fatty liver or compartment where it is easier to
enter than to leave. It is interesting that it is primarily affected by its removal
rate k32 which is smaller in parameter value than its influx rate k23.
The y4 variable being primarily affected by a is not very surprising due to the fact
that this is the only parameter that affects this variable in the equations. This
should be the same for y1 and k12 but according to the paired t test this variable
is also affected by a. This outcome could be due to very small difference average
being divided by a tiny standard error leading to a large T statistic causing a
false positive.
For the Cytochrome P450 cycle within the first few variables it is not easy to see
which parameters have a larger effect even though the primary parameters would
have an effect right away i.e. k1, k−1, k2 etc but the later variables like [FSO2]
the issue becomes clearer with only two out of the twelve parameters being high-
lighted. In order to try and see through this issue it would be necessary to run
the cycle for longer in order for the difference to truly become clear.
The sensitivity ranges show smaller one parameter being outlined but sometimes
the one selected does not have a direct effect on the concentration like k3:[E] and
k3:[S] etc. These can be explained by a rolling effect i.e. k3 affects [FS] which in
turn influences the [GSO2] level and [HSO] level and so on.
The extended sensitivity shows that k3 is a controlling factor although this does
not affect all the variables directly. The t test by contrast shows that k5 is also
a parameter that has and effect on multiple variables. Due to this model being a
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cycle it is difficult to know what parameters truly affect each variable the most
unless the model is run for much longer or a stronger measure of sensitivity is
used.
The Cytochrome P450 model is an amalgamation of the last two models so it is
thought that the same sensitivities would be held with slight adjustments due to
model 3‘s y3 disappearing and joining with the drug level [S].
The y1 and y3‘s sensitivity to parameters are left the same from model 3 (y3 is
the same as y4) but y2 is now affected by k6 which is due to the joining with the
CYP cycle. As with the previous model the fuzziness in the parameter sensitivity
comes at the end. This means that if the last model needed longer then this one
does as well.
The extended sensitivity analysis shows that k23 is a prominent parameter, which
is sensible as it regulates transfer between y2 and [S]. For the paired t test the
prominent parameters are k6 and k9 which control the passage from HSO to EP
and E respectively. The variables for which the Magnitude test seems to have
worked in minimising the parameter effect to 1-4 parameters are y1, y2, y3 and
[S]. For these concentrations the rates that were singled out were accurate since
all the parameters directly affect the variable.
The analysis outlined in this chapter allows for prominent parameters to be iso-
lated and to see how robust the models are to experimental error and parameter
estimation. For the first three models the parameters that have the greatest
sensitivity are easily found and there is agreement between the tests performed.
Unfortunately for the larger models these tests do not agree and as such for all
but a few variables it is unclear what parameters are powerful.
The first three models were applied to experimental data in Chapter 3. The anal-
ysis in this chapter shows with respect to model 2 the shifts between the HRN and
WT parameter sets are most visible in y2 if the excretion rate k20 changes. For
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model 3 this is the k32 parameter representing the influx from the third compart-
ment or “fatty liver“. This particular change is visible in the Tamoxifen models,
which can be found in section 3.3.9. The techniques for finding the sensitive
parameters outlined in this chapter are easily applied and return good results so
long as the model is simple enough. It is possible that the difference taken of
10% in the parameters is too small to gain insight into the larger models.
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Chapter 5
Cellular Automaton Models
5.1 Introduction
Cellular Automaton (CA) models have been used for a number of years now since
John von Neumann and Stanislaw Ulam first introduced them in the middle of
the last century. These models are a mathematical representation of real life
systems usually in physics and biology where space and time are discretised.
This is done using a lattice and each site takes on specific values corresponding
to rules laid down by the programmer, which include boundary conditions and
neighbourhood searching. The algorithm is evaluated at discrete time steps in
order to update sites simultaneously (Wolfram, 1983). Cellular Automata can
use 1D, 2D and even 3D lattices which allow for greater complexity in the model
(Sigmund, 1993).
Rules are used to define state values in step t+1 dependent on nearest neighbour
values in step t (Wolf-Gladrow, 2000). As such there are numerous rules that
can be used in order to do this since there is no restriction on the type they
can use (Raabe, 2004). In one dimension it can be shown that if you have eight
different states with two options (on or off) there are 256 rules used in the cellular
automaton.
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In Wolfram (1984) four classes of 1D cellular automata and their corresponding
rule set were outlined. The class 1 cellular automata evolve to a homogeneous
state in a finite number of steps. Class 2 and class 3 show periodic and aperiodic
behaviour respectively. In the final class the cellular automaton creates periodic
and propagating stable structures, which can exist for arbitrary lengths of time
Although four classes were defined, only three have been found (Bak, 1997) -
the other being propagating complex patterns forever. This is an area of much
debate and it has been proposed that a better classification system maybe needed
(Barbosa et al., 2006).
Different types of cellular automata
Traditional cellular automaton models are deterministic but due to the rules be-
ing unrestricted this allows for greater variation. For example the lattice can be
triangular, square or hexagonal in shape. The other part of the definition that
can be different is the neighbourhood searching algorithm. This can be either von
Neumann or Moore which gives either a diamond or square shape respectively to
the cells on the lattice when they propagate.
For processes in physics like fluid dynamics it is better to use a more specific
cellular automaton like Lattice Gas (Kutrib et al., 1997). The HPP (Hardy, de
Pazzis and Pomeau) lattice gas model is an important model in physical systems
using statistical properties of particles (Wolf-Gladrow, 2000; Bandini et al., 2001).
Lattice Boltzmann models are useful in fluid dynamics as well, although this is
due to the automaton having a continuous state space. As such this type of model
cannot be thought of as a strict cellular automaton model (Bandini et al., 2001).
Biological problems were the reason for the first cellular automaton to be designed
(Bandini et al., 2001). These models have been used to model a wide range of
applications from fluids in physics to cell growth in biology and medical studies.
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Tumour growth has been a focus of cellular automaton modelling in recent years.
For example, Dormann and Deutsch (2002) used a hybrid lattice-gas cellular au-
tomaton in order to model pattern formation in multicellular tumour spheroids.
They showed that the self-organized growth of the cells caused a three layer
formation within the sphere. These layers represented a necrotic core with a qui-
escent layer and proliferating rim around it. There was no cell flow towards the
core only outwards towards nutrients since all cells in the core were in the resting
phase. This paper also shows that it is necessary to include interaction with more
than just the cell‘s nearest neighbours.
Using an extended Potts model, Turner and Sherratt (2002) investigated malig-
nant invasion to see how cell adhesion at its core affects invasiveness. In Ghaemi
and Shahrokhi (2006) an attempt was made to combine a cellular Potts model
and Lattice-Gas cellular automaton to simulate avascular tumour growth.
Ward and King (2003) also studied multicellular spheroids using a purely PDE
based model. They studied the difference in survival rates between a spheroid
and a monolayer when a drug was applied. As can be expected the survival rate
was higher in the spheroid since drug penetration was lower.
Another case where a cellular automaton model has been used to investigate drug
therapy on tumour cells was shown in Ribba et al. (2004). While studying non-
Hodgkins Lymphoma a vascular network was included in their algorithm. This
allowed for blood flow to have an effect on the drug treatment. However, the
tumour growth was found to be unstable which caused oscillations in cell colony
number.
Multi-scale models have been used in the literature in order to account for both
cell-cycle dynamics and diffusion of therapeutic drugs. In Alarcon et al. (2004) a
model for tumour growth was proposed which included blood flow and cell-cycle
dynamics with vascular adaption. Ribba et al. (2006) also developed a multi-scale
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model but this time of avascular tumour growth, which included spatial tumour
dynamics using Darcy’s law. It also included radiosensitivity due to cell cycle
phase.
Sinek et al. (2009)use a multicompartment Pharmacokinetic-Pharmacodynamic
(PKPD) model to investigate the efficacy of Doxorubicin and Cisplatin. They sug-
gest that spatial heterogeneity in nutrient and oxygen distribution is necessary
for realism. This is due to microenvironments exist within tumour spheroids.
In Frieboes et al. (2009) a mathematical model was presented that included a
three dimensional physical morphology to tumour growth. This allowed them to
investigate the different physical scales in order to predict the response to breast
cancer drugs e.g. Doxorubicin.
In Bearer et al. (2009) a multiscale tumour growth model was proposed which
included morphology, genotype and phenotype as well as nutrient and oxygen
heterogeneity. This 3D model showed that tumours to exhibit morphological in-
stability resulting in finger shaped protrusions which are found in vivo.
Ermentrout and Edelstein-Keshet (1993) produced a good review of models from
biologically inspired cellular automata, which include areas such as neuroscience
and population biology. Another good review of cellular automaton theory that
provides a good background is by Kari (2005).
In this chapter a traditional cellular automaton is used with an on-lattice ap-
proach. It is a multi-scale model with individual cells on the lattice having an
internal cell cycle and also a Cytochrome P450 cycle. In the following sections is
held a description for both the cell cycle and the P450 cycle models.
5.2 Background Theory to the Multiscale Model
The background to the Cytochrome P450 cycle and functionality can be found
in section 1.4.
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5.2.1 The Eukaryotic Cell Cycle
The cell cycle is a biological mechanism that describes the stages an individual
cell goes through in order to divide and produce daughter cells.
Figure 5.1: Schematic diagram of the cell cycle.
The cell cycle is usually divided into four stages (shown in figure 5.1), which
are known as the M, G1, S and G2 phases. The M phase represents Mitosis
where nuclear division occurs and two identical daughter cells are created. The
G1 phase is the part of the cell cycle concerned with growth and biosynthesis
whereas G2 is mostly just growth. DNA replication happens in the Synthesis (S)
phase, which occurs between the G1 and G2 phases. The other state shown in
the cycle is that of the resting phase G0. This is where the cells, which are not
proliferating or dormant, are categorised. The length of stay in the G0 phase can
be of any length.
Mathematical models have been created over the years with varying levels of
complexity. The model by Novak and Tyson (2004) includes eighteen differential
equations for the eukaryotic cell. The cell cycle used in this chapter is a previous
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less complex version and is governed by the six differential equations in a model
proposed by Tyson and Novak (2001). The six components include differential
equations for the Cdk-CyclinB complex (CycB), APC-Cdh1 complex (Cdh1), the
Plk1 protein (Plk1), the cell mass (mass) and the p55cdc-APC complex - both
the active and total levels (B=p55cdcA and A=p55cdcT respectively).
The CycB complex can be expressed in the following equation:
d[CycB]
dt
= K1 − (K ′2 +K
′′
2 [Cdh1])[CycB] (5.1)
The complex is decayed both naturally and based on the Cdh1 complex level.
d[Cdh1]
dt
=
(K
′
3 +K
′′
3 [B])(1− [Cdh1])
J3 + 1− [Cdh1] −
K4m[CycB][Cdh1]
J4 + [Cdh1]
(5.2)
The equation for [Cdh1] shows Michaelis-Menten dynamics for both activation
and inactivation of the complex. It is activated by the active version of p55cdcA
and inactivated by [CycB].
d[A]
dt
= K
′
5 +K
′′
5
([CycB][mass])n
Jn5 + ([CycB][mass])
n
−K6[A] (5.3)
The total p55cdc has a Hill function in the equation explaining the transcription
of total p55cdc turned on by [CycB] and other than that it is naturally degraded.
d[B]
dt
=
K7[Plk1]([A]− [B])
J7 + [A]− [B] −
K8[Mad][B]
J8 + [B]
−K6[B] (5.4)
Just like [Cdh1] the equation for active p55cdc contains Michaelis-Menten dy-
namics to explain the activation and inactivation of inactive and active p55cdc
respectively. Protein [Plk1] activates inactive p55cdc and Mad genes inactivate
active p55cdc.
d[Plk1]
dt
= K9[mass][CycB](1− [Plk1])−K10[Plk1] (5.5)
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The [Plk1] protein equation shows a mass proportional inactivation of [CycB] and
a natural degradation.
d[mass]
dt
= µ[mass](1− [mass]
m∗
) (5.6)
The final equation of the cell cycle six component model governs the cell mass by
a logistic growth equation with maximum cell mass m∗.
As the cells are tumour cells the cell cycle needed to be longer than the 63.05mins
outlined in the paper. Cancer cells have cell cycle lengths, which vary from 15
hours to 10 days. Smith and Martin (1973) proposed that the difference in cell
cycle length was due to the length of stay in the G0 phase. This means that if
there was no stay in the G0 phase the cell cycle length would be shorter and vice
versa. In Novak and Tyson (2004) the rate constants were changed from min−1
to hr−1 changing the time scale to be changed to hours as well. This allows the
change of cell cycle length to 63.05 hours for the following model, which is within
the range for human cancers.
The parameters used for the cell cycle model are outlined in table 5.1.
Component Rate Constants (hr−1) Dimensionless Constants
[CycB] K1=0.04, K
′
2=0.04, K
′′
2=1 [CycB]threshold=0.1
[Cdh1] K
′
3=1, K
′′
3=10, K4=35 J3=0.04, J4=0.04
[A] K
′
5=0.005, K
′′
5=0.2, K6=0.1 J5=0.3, n=4
[B] K7=1, K8=0.5 J7=0.001, J8=0.001, [Mad]=1
[Plk1] K9=0.1, K10=0.02 -
[mass] µ =0.01 m∗=10
Table 5.1: Cell Cycle Parameters.
In order to include variability affecting the cell growth rates white noise was
added to µ shown in the following equation. The variable µ is a measure of nu-
trient, oxygen and growth factor level for the grid point.
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µ = µ+ + εµ̂ (5.7)
Where µ+ = 0.01, ε=0.005 and µ̂ ∼ U(−1, 1). This allows for cells to divide
faster or slower than the general population on the lattice. This equation shows
that µ varies from 0.005 to 0.015 if the cell was experiencing normal cell growth
due to the presence of ample nutrient, oxygen and growth factor. However if the
cell has no space around it the µ parameter is set to zero meaning that these
levels have dropped.
5.2.2 The Cytochrome P450 Cycle
As seen from the previous section, the Cytochrome P450 cycle is characterised
by chemical equilibria (1.1) to (1.9). Using the law of mass action it is possible
to transfer these equilibria to a set of ordinary differential equations. For exam-
ple, while focussing on the variable [E] that represents enzyme concentration, the
reactions involving this are:
Equation Rate Constants
E + S → ES k1
ES → E + S k−1
EP → E + P k7
E + P → EP k−7
GSO2→ E + S +H2O2 k8
HSO → E + S +H2O k9
Table 5.2: P450 Enzyme Equations.
This means that the differential equation describing the rate of change of en-
zyme concentration is:
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d[E]
dt
= k−1[ES] + k7[EP ] + k8[GSO2] + k9[HSO]− k1[E]− k−7[E]
= k−1[ES] + k7[EP ] + k8[GSO2] + k9[HSO]− (k1 + k−7)[E] (5.8)
Using the same methodology with the rest of the variables, the following system
of ordinary differential equations is obtained:
d[S]
dt
= k−1[ES] + k8[GSO2] + k9[HSO]− k1[S] (5.9)
d[ES]
dt
= k1[E][S]− (k−1 + k2)[ES] (5.10)
d[FS]
dt
= k2[ES] + k−3[FSO2]− k3[FS] (5.11)
d[FSO2]
dt
= k3[FS][O2]− (k−3 + k4)[FSO2] (5.12)
d[GSO2]
dt
= k4[FSO2]− (k5 + k8)[GSO2] (5.13)
d[HSO]
dt
= k5[GSO2]− (k6 + k9)[HSO] (5.14)
d[EP ]
dt
= k6[HSO] + k−7[E][P ]− k7[EP ] (5.15)
d[P ]
dt
= k7[EP ]− k−7[P ] (5.16)
The parameters in the original paper of Guengerich (2001) have units min−1.
These had to be adjusted to match the units in the cell cycle model which are
hr−1. Table 5.3 below shows the converted values.
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Parameter Value (hr−1) Parameter Value (hr−1)
k1, k−3, k7 6000 ∗ 60 = 360000 k−1 120000 ∗ 60 = 7200000
k2, k4 700 ∗ 60 = 42000 k3 6 ∗ 60 = 360
k5 110 ∗ 60 = 6600 k6 33 ∗ 60 = 1980
k−7 660 ∗ 60 = 39600 k8, k9 50 ∗ 60 = 3000
Table 5.3: P450 Cycle Parameters.
The substrate used for this cycle is taken to be an externally administered
drug.
Cytochrome P450 Model
In order to achieve this a hybrid model was adopted which combined the model
3 shown in section 3.2.3 configuration with the Cytochrome P450 cycle. This
model had the following equations:
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dy1
dt
= −k12y1 (5.17)
dy2
dt
= k32[S] + k12y1 − k23y2 − y3 (5.18)
dy3
dt
= a (5.19)
d[E]
dt
= k−1[ES] + k7[EP ] + k8[GSO2] + k9[HSO]− (k1 + k−7)[E] (5.20)
d[S]
dt
= k23y2 + k−1[ES] + k8[GSO2] + k9[HSO]− (k1 + k32)[S] (5.21)
d[ES]
dt
= k1[E][S]− (k−1 + k2)[ES] (5.22)
d[FS]
dt
= k2[ES] + k−3[FSO2]− k3[FS] (5.23)
d[FSO2]
dt
= k3[FS][O2]− (k−3 + k4)[FSO2] (5.24)
d[GSO2]
dt
= k4[FSO2]− (k5 + k8)[GSO2] (5.25)
d[HSO]
dt
= k5[GSO2]− (k6 + k9)[HSO] (5.26)
d[EP ]
dt
= k6[HSO] + k−7[E][P ]− k7[EP ] (5.27)
d[P ]
dt
= k7[EP ]− k−7[P ] (5.28)
(5.29)
The parameters used are outlined in the following table:
Parameter Value
k12 1
k23 0.4
k32 0.175
a 0.4
Table 5.4: Cytochrome P450 Model Parameters.
For this model the cell killing protocol was transferred to the level of y2 in-
stead of [S]. The plots of the growing tumour are shown in figure 5.20.
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5.2.3 Computational Simulation Method
The cellular automaton model was coded in Java, which means it can be run on
any platform. This model starts with an empty grid of 51 by 51 squares with
∆l = 0.04mm and a cell in G1 phase in the middle as shown in figure 5.3. The
grid point size is within the size range set out in the work in Melicow (1982).
This paper stated that normal cancer cells have a range of 10100 µm and the ∆l
is within this. The grid is a regular square lattice and each grid point contains
either a empty space or a cell. The cell can take five different states: G1, S, G2,
M, or G0. The levels and progression is shown in the following figure:
Figure 5.2: Schematic diagram of the possible states for a cell in the cellular automa-
ton.
This gives four states in all that each grid point can take.
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Figure 5.3: Schematic diagram of the configuration of cells on the cellular automaton
grid.
A fourth order Runga-Kutta algorithm was used at each time step to get the
intercellular protein levels in each cell using the model outlined in equations (5.1)
to (5.6). Within the program there are 1000 time steps for each hour of simula-
tion. This is the same for both the Cytochrome P450 cycle and cell cycle. After
this, the phase of the cell and division signal is added to the grid square infor-
mation. The cell is marked for division when [CycB] > 0.1 and then the mass
is halved. The threshold for the [CycB] protein was calculated from numerical
simulations of the cell cycle model shown in the work by Gordon (2006). The
work showed that this protein dips below 0.1 just before the mitosis phase begins.
If this happens then neighbourhood searching techniques are used to find space
and if no space is found a marker is added to the grid point and this causes µ to
be zeroed and the cell to enter G0 phase. Even if the cell has not been marked
for division, the code checks for space to the order of three spaces away from the
cell. In order to avoid the artificial effect of the grid structure on the growth
of the tumour, the cancer cells grow and spread using the Moore algorithm and
von Neumann algorithm alternately i.e. at one time step the Moore algorithm
is used and at the next time the von Neumann algorithm is used and so on. As
was mentioned in the introduction these two neighbourhood searching techniques
154
have different shape outcomes due to the number of neighbours analysed. Moore
looks at all eight neighbours leading to a square shape and von Neumann the 4
neighbours to the north, south, east and west, which gives a diamond shape. The
alternation between these two techniques result in a more circular shape for the
tumour growth.
The external substrate (i.e. the drug), [S], diffuses from the right boundary across
the domain according to the following equation:
δ[S]
δt
= d
δ2[S]
δx2
− λ[S] (5.30)
where d is the (constant) diffusion coefficient and λ is the decay rate of the drug.
This equation is used in conjunction with equation (5.9) in order to control the
drug level. The diffusion coefficient used was d = 0.1875 and the decay rate
λ = 0.005. This equation is solved by a forward-time-central-space finite differ-
ence method.
The P450 cycle only acts when there is a cell present in the square on the grid
and these cells start with an enzyme level of 3. The other variable in the model
is that of the oxygen level. The default is [O2] = 1 per grid square with d[O2]
dt
= 0.
Drug induced cell death is programmed through identifying the drug level in the
cell and if this value is greater than the active concentration set there is a prob-
ability for this grid point to be emptied or “killed“. The drug algorithm includes
a cell cycle phase-specific anti-cancer drug, which kills cells with a probability of
0.8. It is currently assumed that a cell in M-phase (which is found using the grid
square information) is probably killed if the drug concentration is above 0.0001.
Once the drug level drops below this threshold the tumour grows unhindered.
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5.3 Computational Simulation Results
Initially, the tumour is allowed to grow and develop for two hundred hours (using
the cell-cycle equations). After this time, the drug is delivered by one of the three
delivery regimes and undergoes diffusion according to equation (5.30).
Three dosing regimens were applied to the tumour that was grown to, these
were: (i) a single dose of drug released from the first two leftmost columns (2∗51 =
102 squares) of the grid, (ii) a constant infusion of drug released from only the
first leftmost column on the grid, and (iii) a single dose of drug released from the
central ten by ten square which is equivalent in size to the side dose.
As well as the three different dose regimes, the time of delivery was changed
between -10, +0 and +10 hours after the tumour had grown for the side and
central dose regimes.
Plots of the growing tumour are made at +5, +15, +25, +35 and +45 hours after
drug dosage time and these pictures are shown in figures 5.5, 5.7, 5.9, 5.11, 5.13,
5.15 and 5.17. From figures 5.8, 5.12 and 5.16 it can be observed that there is a
difference when using the P450 cycle which is carried through the entire period
of the algorithm. For the central and side dosing regimens the dosage time was
changed in order to analyse how a shift of 10 hours could affect the efficacy of
the drug. The drug curves relating to this are shown in figures 5.14 and 5.10
respectively In the plots of the growing tumour, the blue cells represent those
in G1 phase, green cells are those in S-G2-M phase and black are in the resting
phase G0.
5.3.1 Effect of Changing the Drug Diffusion Coefficient
To see the impact on the growing tumour through changing the value of the drug
diffusion coefficient, the value was changed by a factor of ten from a baseline
value i.e. we carried out computational simulations with d = 0.0025, 0.025, 0.25.
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The drug uptake curve for these three scenarios is shown in figure 5.4. The plots
in figure 5.5 show the effect on the growing tumour.
Figure 5.4: Plots of average drug concentration over time with different drug diffusion
coefficients d.
The plots of the drug curve show that as the diffusion parameter increases
the drug concentration is reduced. This means that the active drug is around for
a shorter period of time when d is larger which suggests that it diffuses away too
quickly to have as much effect on the cells.
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5 hr 15 hr 25 hr 35 hr 45 hr
Figure 5.5: Plots showing the effect on the growing tumour of changing the drug
diffusion coefficient d - d = 0.0025 (top), d = 0.025 (middle) and d = 0.25 (bottom).
Blue cells represent those in G1 phase, green cells are those in S-G2-M phase and black
are in the resting phase G0.
Although it seems that it is cells in the resting phase G0 are being destroyed
this is not the case. This effect is caused by the cells being killed while in M phase
and the cells left alive ending up in G0 due to lack of resources near the centre.
The top two lines of tumour snapshots showed that the drug has not been able to
diffuse to the cells at the lower diffusion parameter values. This is an interesting
result since this suggests that the decay section of the diffusion equation in 5.30
affects the curve more when the diffusion parameter is smaller i.e. d δ
2[S]
δx2
<< λ[S].
This is related to the diffusive length, which is defined as:
L =
√
d
λ
(5.31)
From this equation it can be seen that if the diffusion is doubled the diffusion
length increases by a factor of
√
2. This property would explain why the last
line is the only one that shows cell death across the tumour. As such if the
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diffusion parameter is less than 0.25 with a decay rate of 0.005 the tumour is
more susceptible to a lower drug concentration (less than active threshold) and
when this occurs the tumour grows unheeded.
5.3.2 Effect of Changing the Drug Decay Rate
To see the impact on the growing tumour through changing the value of the drug
decay rate λ, the value was changed by a factor of ten from a baseline value i.e.
carried out computational simulations with λ = 0.0005, 0.005, 0.05. The corre-
sponding drug uptake curves are shown in figure 5.6. The plots in figure 5.7 show
the effect on the growing tumour.
Figure 5.6: Plots of average drug concentration over time with different drug decay
rate λ.
The drug concentration curves show that as the decay parameter increases
there is less drug in the system. This means that when drug decay is large it has
less killing effect on the tumour.
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Figure 5.7: Plots showing the effect on the growing tumour of changing in the decay
parameter – λ = 0.0005 (top), λ = 0.005 (middle) and λ = 0.05 (bottom). Blue cells
represent those in G1 phase, green cells are those in S-G2-M phase and black are in
the resting phase G0.
The plots of the snapshots of the tumour mass show that as the decay pa-
rameter increases the tumour is bigger since there is a lower drug concentration
around to have a killing effect. Although this is understandable due to the nature
of a decay component of an equation i.e. as the parameter gets bigger the decay
gets larger. However due to this not being the only component in the equation
the decay would have to be large enough in order to counter-balance the diffusive
nature of the equation. This is why the drug concentration level seems to have
no effect in the final line of figure 5.7 d δ
2[S]
δx2
>> λ[S]. As before when related
to the diffusion length an double in the value of λ in equation 5.31 equates to a
shortening of diffusive length by a factor of
√
2.
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5.3.3 Application of the Drug via a Single Dose Released
from the Boundary
For this dosing regimen the drug uptake curve is shown in figure 5.8.
Figure 5.8: Comparison of average drug concentration with and without the P450
Cycle under the single dose release from the boundary.
It can be seen from this plot that there is a difference in the curves when the
CYP cycle is included in the program. The two curves show similar dynamics
although after the 0.1 hour point the “+P450 Cycle“ curve drops below the “-
P450 Cycle“ curve. This is probably to do with the cycle equations (5.8) to (5.16)
because the drug level is related to enzyme and enzyme-drug complex level. The
equilibrium in equation (1.1) shows how these three chemicals are related. The
inclusion of the Cytochrome P450 enzymatic cycle in the program allows for an
added level of complexity that has resulted in interesting outcomes.
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Figure 5.9: Plots showing the tumour mass at various times for the single dose release
from the boundary: With (top) and Without (bottom) P450 Cycle. Blue cells represent
those in G1 phase, green cells are those in S-G2-M phase and black are in the resting
phase G0.
The change between the top and bottom rows are due to the inclusion of the
enzymatic cycle and the plots shown in figure 5.9 outline the effect of the drug
level on the tumour cells. The top row shows that the tumour is slightly smaller
with the P450 cycle. However the black cells (resting phase, G0) appear earlier in
the top row than in the bottom row and the last picture shows the largest amount
of them in both rows. The morphology of the tumours are different between the
two lines and this is attributable to the kill and regrowth mechanism inherent to
the program. The right hand side of the tumours in the top line is a lot wider due
to cell proliferation that has been left untouched by the cell killing algorithm.
Effect of Changing the Time of Dose
The plot showing the different drug curves for the changes in time of dosing is
given in figure 5.10.
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Figure 5.10: Plots of average drug concentration over time with three different times
of dose application.
The plot shows that although the dosing time was changed the shape and
peak height of the curve remains unchanged. This does not mean however that
there would not be differences in the shape of the tumour due to the timing of
the dose since the drug would be more effective on a smaller tumour and vice
versa.
163
5 hr 15 hr 25 hr 35 hr 45 hr
Figure 5.11: Plots showing the effect on the growing tumour of changing the time
of dosage: -10 hours (top), +0 hours (middle) and +10 hours (bottom). Blue cells
represent those in G1 phase, green cells are those in S-G2-M phase and black are in
the resting phase G0.
The plots of the tumour cells are shown in figure 5.11 and the rows are what
would be expected of a time shift of ten hours (-10, +0 and +10 hours). The
other result is that as the time of drug dose is earlier or delayed, the tumour
changes size. This could be more to do with the fact that the tumour the drug is
applied to is not fully grown. Since the drug curves are similar in shape the drug
pressure would be similar in each line but occurring at different points before the
start of row 1, start of row 2 and after picture 1 in row 3. The G0 cells appear to
be more prevalent in the -10 hours and +0 hours snapshots, which could be due
to regrowth after the cells had been killed, or the drug level has dropped below
the active threshold. This is an interesting result as it shows how the tumour
cells proliferate with or without the drug being present.
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5.3.4 Application of the Drug via a Single Dose Released
from the Centre of the Domain
For this dosing regimen the drug uptake curve is shown in figure 5.12 and there
are marked differences between this plot and the one for side dose (figure 5.8).
These are probably to do with the fact that the P450 cycle is active straight away
so causes the peak and dip in comparison to the ‘-P450’ curve.
Figure 5.12: Comparison of With and Without P450 Cycle average drug concentration
with the Central Dose Regimen.
5 hr 15 hr 25 hr 35 hr 45 hr
Figure 5.13: Tumour snapshots for the Central Dose Regimen: With (top) and With-
out P450 Cycle (bottom). Blue cells represent those in G1 phase, green cells are those
in S-G2-M phase and black are in the resting phase G0.
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The plots shown in figure 5.13 demonstrate what the drug level does to the
tumour cells. There is similarity between the two rows for the first three snapshots
but for the last two there are significant differences. The final snapshots in the
bottom row show a less circular shape on the outside than the corresponding
pictures in the top row. This would suggest that the cells are growing outwards
as well as inwards. This is interesting as it would be easy to assume that the
tumour would try to strengthen the inner core before expanding as was seen in
the top row of 5.11. Although the snapshots are only 2D it may show another
aspect of tumour cell regrowth when looking in 3D models.
Effect of Changing the Time of Dose
The plot showing the different drug curves for the changes in time of dosing is in
figure 5.14.
Figure 5.14: Plots of average drug concentration over time with three different times
of dose application.
The curve for ’+10 hrs’ curve is much higher than ’+0 hrs’ but this difference
is much larger than the distance between ’-10 hrs’ and ’+0 hrs’.
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Figure 5.15: Plots showing the effect on the growing tumour of changing the time
of dosage: -10 hours (top), +0 hours (middle) and +10 hours (bottom). Blue cells
represent those in G1 phase, green cells are those in S-G2-M phase and black are in
the resting phase G0.
The snapshots of the cell grid are shown in figure 5.15 and the three rows have
similar pictures but shifted horizontally since the dosing time is different for each
row. This is similar to the side dose time change shown in section 5.3.3 but there
is a difference in the shape of the tumours due to the location of the drug dose.
In the top line there is a higher proportion of G0 cells in the final snapshot and
although there are these cell types in the other two lines it is not as pronounced.
It was expected that if the tumour had more time to grow in the absence of drug
it would cause the size to be bigger. This does not seem to be the case with
the central dose since the tumour seems to be fragmented in the final line but
no larger. This could be due to the peak level in the drug concentration being
greater for the later dose times and as such the cells are killed more effectively.
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5.3.5 Application of the Drug via a Constant Dose Re-
leased from the Boundary
The uptake curve for the drug in the case of constant dose released from the
boundary is shown in figure 5.16.
Figure 5.16: Plots showing average drug uptake With and Without P450 Cycle in
the case of a constant dose released from the boundary.
The graph has the same time axis as the other two dosing regimes in order to
aid in comparison between them. This curve is different to the plots for the other
dosing regimens shown in figures 5.8 and 5.12 since the drug level continues to in-
crease over the entire fifty hour stretch of code time (one hour = 1000 time steps).
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Figure 5.17: Tumour snapshots for the Constant Side Infusion Regimen: With (top)
and Without (bottom) P450 Cycle. Blue cells represent those in G1 phase, green cells
are those in S-G2-M phase and black are in the resting phase G0.
The plots of the growing tumour are shown in figure 5.17 and it is easy to see
the effect of the P450 cycle on the tumour. As with the previous simulations the
CYP cycle causes the drug level to be lower over time and as such the tumours
tend to be bigger. For the two rows the drug interaction with the tumour cells is
one of annihilation, which has resulted in half moon shaped tumours especially
in the bottom row. This suggests that the tumour cells do not have the ability
to regrow due to the constant pressure of the program‘s kill command.
5.3.6 Effect of Changing the Oxygen Level
Three different oxygen levels were used - 0.3333, 0.6667 and 1 in order to investi-
gate the impact of the oxygenation on the P450 cycle. The product concentration
curve was used for the three levels since the drug level for each showed no change
and these curves are shown in figure 5.18. The snapshots in figure 5.19 show the
different effects on the tumour cells.
169
Figure 5.18: Plot showing the effect of oxygen level change on the average drug and
product concentration.
The curves show that even though the change in oxygen level across the grid
has little to no effect on the drug ([S]) level it has an effect on the product ([P]).
The effect on the product is due to a knock-on effect from the FSO2 level in the
cell - the higher oxygen level causes more product to be produced.
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Figure 5.19: Plots showing the effect on the growing tumour of changing the time
of dosage: oxy=0.3333 (top), oxy=0.6667 (middle) and oxy=1 (bottom). Blue cells
represent those in G1 phase, green cells are those in S-G2-M phase and black are in
the resting phase G0.
The snapshots show very little variation between the rows and this is due
to the drug level not being dependent on the oxygen level change as shown in
figure 5.18. Since the killing of cells is dependent on the drug level being above
the active threshold the only randomness comes from the probability of death
(p=0.8) and this has caused the variation seen in the snapshots.
5.3.7 Extended Cytochrome P450 Model for Drug Metabolism
Since the drug level in the program seemed to dissipate quite quickly (one hour)
an attempt to add a delay to the Cytochrome P450 cycle was made.
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Figure 5.20: Tumour snapshots comparing CYP cycle (top) and CYP model (bottom).
Blue cells represent those in G1 phase, green cells are those in S-G2-M phase and black
are in the resting phase G0.
Due to the bottom row of the tumour snapshots showing little or no drug
induced cell death it shows that the drug level must not rise above the active
threshold for very long.
5.4 Discussion
This chapter has presented a multiscale mathematical model of solid tumour
growth. It combined a cellular automaton model for the growing tumour cells
with ordinary differential equations governing internal concentrations of proteins,
the cell cycle and the P450 enzymatic cycle. Each individual automaton cell rep-
resented a single tumour cell. The effect of treating the tumour with a drug was
considered and was allowed to diffuse across the spatial domain in different ways.
The curves shown in this chapter are averages across grid curve rather than on
a particular grid square. It would be useful to know what happens on each grid
square but it is computationally demanding.
The changes in the Drug diffusion coefficient and the decay showed results, which
are related to the diffusion length. This means that as d increases or λ decreases
the length of diffusion extends by a factor of
√
2 meaning more cells across the
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tumour are killed by the program.
The different regimens have shown a number of aspects of the model’s applicabil-
ity. The side and central dosing regimes results differ due to proximity of tumour
tissue to the dose squares. The central dose is more efficient at killing the cells in
the centre of the grid, which is understandable due to its definition. Other than
this difference there is a change in drug level since when the drug is on a grid
square where a cell is present the P450 cycle acts and temporarily heightens the
drug level. However this is short lived as the P450 cycle causes the drug to be
lower than without the cycle.
The constant side infusion works well to kill the tumour but is not feasible since it
is not possible to set up in real life. In real life chemotherapy the dosing strategy
tries to limit the amount of systemic damage caused by the cytotoxic drugs. This
is done by locating the tumour and injecting as close as possible, which would be
analogous to the central dose if close and the side dose if the drug has to diffuse
towards the tumour.
The oxygen level affects the tumour‘s growth in two different ways through the
cell cycle where nutrient levels affect protein and the P450 cycle in the step de-
scribed by equation 1.3. In the cell cycle this is controlled by the variation in the
µ parameter which can be affected by lack of space within the tumour this is
what can cause the generation of the necrotic core. The oxygen component in the
P450 cycle affects the product level but not the drug itself since the reaction it is
involved in is later on in the cycle. This means that if the program was used for
a prodrug where the [P] level is important the oxygen level would play a larger
role in determining efficacy.
The drug curves unfortunately are very short in duration for this system, which
is not useful since only a few drugs have a short half life in the human body.
The half life of the curve being about 20-30 minutes is comparable to drugs like
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Cisplatin (Zahra et al., 2008).
In order to fix the brevity of the drug concentration the Cytochrome P450 model
was proposed as a way of delaying the transport of the drug through the tumour.
The Cytochrome P450 model is a useful application since it delays the drug level
change but the parameters and dose level need adjusting since it does not rise
high enough to kill many tumour cells. It is possible that the model needs a dif-
ferent parameter set or more complexity in order to delay the drug elimination.
The drug diffusion, dose and decay are currently arbitrary and therefore not re-
lated to any drug in particular. It is intended to make this more realistic by
relating these parameters to known properties of actual drugs using half lives ob-
tained through in vitro and in vivo diffusion experiments. Diffusion coefficients
are related to both the size of the molecule and the functional groups. It is diffi-
cult to estimate this coefficient since these two properties vary between chemicals.
Diffusion experiments with agar are difficult to compare with different tissue me-
dia. Functional group specificity can cause issues in prediction since it can mean
the drug reacts in the wrong part of the organism.
The tumour snapshots shown within this chapter have confirmed that a rota-
tion of Moore and von Neumann algorithms for neighbourhood searching gave a
rounder tumour. The only pictures that seem to refute this are when the tumour
has grown large enough to meet the sides of the grid giving a diamond shaped
tumour (e.g. Figure 5.5).
This program is applicable to other areas other than the one stated here. For
example any area that deals with interactions between tissue media and drugs
like in toxicology and drug studies.
The cell cycle inside the code deals with tumour cells but this code can be re-
parametised to concentrate on other types of cell including normal cells, hepatic
tissue etc.
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Instead of a mammalian cell structure it could be a yeast cell or a xylem cell
in order to investigate growing structures in the plant kingdom as well as the
animal. As such it could be used as part of a multi-system approach to drug
metabolism if the action of the drug is roughly known.
Other enzymatic systems can be used instead of or as well as Cytochrome P450
e.g. UDP glycosyltransferases (UGTs). This would allow for greater flexibility
in substrate use as many drugs use multiple enzyme systems for their metabolism.
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Chapter 6
Mathematical Modelling of a
Drug Uptake in a Single Cell
In the previous chapters the temporal and spatial effects of the Cytochrome P450
(CYP) enzymes have been investigated and the current chapter focuses on the
effect of the cycle on the cellular level. As such it is the size of one point from the
51 by 51 grid. As mentioned in chapter 1 the CYP enzyme system is located in
the smooth endoplasmic reticulum (SER) (Tsui, 2003). A diagram of a eukary-
otic cell is shown in figure 6.1 and shows the location of the SER.
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Figure 6.1: Schematic diagram of a eukaryotic cell (CliffNotes.com, 2011).
Using COMSOL to model the CYP enzyme system on the cellular level a ba-
sic cell of size 40 µm in diameter was set up as shown in figure 6.2. Using a very
basic cell allows for a better inspection of the cellular level of the enzymatic cycles
effect on drug metabolism since it allows for added complexity to be included in
the enzyme equations. The formulation was solved using Finite-Element Method
on triangles that have been drawn in order to form a fine mesh across the basic
cell setup.
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Figure 6.2: Plot showing the ”mathematical cell” used in the simulations - the figure
shows the different compartments considered i.e. the exterior of the cell, the cytoplasm,
the smooth endoplasmic reticulum and the nucleus.
Region 1 (R1) represents a drug reservoir that has zero-flux conditions on
the external boundaries whereas all the internal boundaries use continuation of
flow principles. The drug, [S], diffuses across the reservoir using the following
equation:
δ[S]
δt
= D∇2[S]− λ[S]
The drug starts off in this section and diffuses towards the cell wall, which is
represented by the boundary of E1 (cytoplasm). All of the objects within this
boundary have the same diffusion equation with a diffusion coefficient of E in-
stead of D, which is set to a tenth of the value. This is due to the fact that within
the cell wall the medium is denser than the outside.
The four kidney shaped objects encircling the nucleus represent the smooth en-
doplasmic reticulum (CO1 to CO4 in figure 6.2) and as such this is where the
P450 cycle equations will be in effect. As has been outlined before the P450 cycle
equations are:
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d[E]
dt
= k−1[ES] + k7[EP ] + k8[GSO2] + k9[HSO]− (k1 + k−7)[E] (6.1)
d[S]
dt
= k−1[ES] + k8[GSO2] + k9[HSO]− k1[S] (6.2)
d[ES]
dt
= k1[E][S]− (k−1 + k2)[ES] (6.3)
d[FS]
dt
= k2[ES] + k−3[FSO2]− k3[FS] (6.4)
d[FSO2]
dt
= k3[FS][O2]− (k−3 + k4)[FSO2] (6.5)
d[GSO2]
dt
= k4[FSO2]− (k5 + k8)[GSO2] (6.6)
d[HSO]
dt
= k5[GSO2]− (k6 + k9)[HSO] (6.7)
d[EP ]
dt
= k6[HSO] + k−7[E][P ]− k7[EP ] (6.8)
d[P ]
dt
= k7[EP ]− k−7[P ] (6.9)
The only other object in the basic COMSOL cell is the nucleus (E2) and since
some drugs on the market attack this part of the cell it would be interesting to
see how drug level in this area is affected. The parameters for the P450 cycle and
the initial conditions are outlined in the following table:
CYP Parameter Value min−1 CYP Parameter Value min−1
k1, k−3, k7 36000060∗512 = 2.306805 k−1
7200000
60∗512 = 46.136101
k2, k4
42000
60∗512 = 0.269127 k3
360
60∗512 = 0.002307
k5
6600
60∗512 = 0.042291 k6
1980
60∗512 = 0.012687
k−7 3960060∗512 = 0.253749 k8, k9
3000
60∗512 = 0.019223
Spatial Parameter Value Spatial Parameter Value
[S]0 in R1 5 [E]0,[ES]0 3
λ 0.009 D 2.5
Table 6.1: Parameters and initial conditions.
From table 6.1 it is visible that the parameters associated with the CYP cycle
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are much smaller than those cited in table 5.3. This is due to a reduction in value
since the equations are reference a single grid point rather than a whole grid so
each parameter is divided by the grid size.
6.1 Results
In figure 6.3 the pictures show a flow of drug into the cytoplasm across the cell
wall and toward the nucleus.
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Figure 6.3: Plots showing the concentration of drug in the cell at times t = 0 (top),
t = 3 (middle) and t=6 (bottom).
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For the set of surfaces shown in figure 6.5 the images represent the initial and
final levels of the drug [S]. The surface plot in figure 6.4 shows the initial Enzyme
[E] level.
Figure 6.4: Plots showing the initial concentration profile of enzyme [E].
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Figure 6.5: Plots showing the initial concentration profile of drug [S] (top) and final
concentration profile of drug [S] (bottom).
The final drug surface shows a bucket shape, which is understandable as the
drug is stored outside the cell and it is gradually diffusing into the cell where it
is metabolised in the SER causing the curved sides.
As well as the surfaces it is also of interest to look at integrated solutions across
the domains i.e. the Nucleus (figure 6.7), Cytoplasm (figure 6.6) and the Smooth
Endoplasmic Reticulum (SER) (figures 6.8 to 6.16). These can give a better idea
of the drug level curve in each internal cell structure and the effect of the CYP
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cycle in the SER.
Drug level (S) in the cytoplasm is shown in figure 6.6.
Figure 6.6: Plot showing the drug uptake curve over time in the Cytoplasm.
This figure shows that the peak in drug for this area of the cell occurs just
before the one-hour point. The shape of the uptake curve shows an absorption
period, which represents the time taken to get from the outside region across the
cell wall and into the cytoplasm.
Figure 6.7: Plot showing the drug uptake curve over time in the Nucleus.
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The nucleus plot shows a early peak, which could suggest pulses of substrate
moving through the cell. The initial peak represents the drug that has made it
through the gap in between the SER modules.
In the SER the P450 cycle is in action so the following integration plots refer to
this structure within the cell.
Figure 6.8: Plot showing the enzyme level over entire time in the Smooth Endoplasmic
Reticulum (left) and the enzyme level for the first burst (right).
The enzyme level drops very quickly in the cell and does not recover within
the time period. The only other dynamic affecting the drug is through the decay
rate in the diffusion equation.
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Figure 6.9: Plot showing the drug uptake curve over time in the Smooth Endoplasmic
Reticulum (left) and the drug uptake during the first enzyme burst (right).
During the first enzyme burst the drug shows an absorption period followed
by elimination/complex creation. After this time the drug level shows a levelling
until the enzyme can return to a high enough level for more metabolism.
Figure 6.10: Plot showing the enzyme-drug complex ES with Iron (III) core over time
in the Smooth Endoplasmic Reticulum (left) and the ES level during the first enzyme
burst (right).
The ES level drops from its initial value very quickly during the enzyme burst
never recovering. This is due to an irreversible transition from ES to FS in the
model equations. This means that the only process by which the complex can be
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made is if the enzyme and drug level are high enough to produce it. As the en-
zyme level is recovering by the end of the time it is quite likely that this complex
will too.
Figure 6.11: Plot showing the enzyme-drug complex FS with Iron (II) core over time
in the Smooth Endoplasmic Reticulum (left) and the FS level during the first enzyme
burst (right).
The FS level peaks during the first enzyme burst and then steadily drops
through reversible oxygenation to FSO2.
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Figure 6.12: Plot showing the oxygenated enzyme-drug complex, FSO2, with Iron
(II) core over time in the Smooth Endoplasmic Reticulum (left) and the FSO2 level
during the first enzyme burst (right).
As with the ES level the FSO2 level drops off during the first enzyme burst
but never recovers due to irreversible creation of GSO2.
Figure 6.13: Plot showing the oxygenated enzyme-drug complex, GSO2, with Iron
(III) core over time in the Smooth Endoplasmic Reticulum (left) and the GSO2 level
during the first enzyme burst (right).
Although the GSO2 level is fairly constant during the first enzyme burst it is
eliminated by the two-hour point through creation of HSO or breaking down into
the enzyme and drug with by-products.
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Figure 6.14: Plot showing the oxygenated enzyme-drug complex after the loss of
water, HSO, with Iron (III) core over time in the Smooth Endoplasmic Reticulum (left)
and the HSO level during the first enzyme burst (right).
The HSO level drops off by the 3 hour point but unlike the GSO2 plots this
complex shows a creation phase from the GSO2 to HSO reaction in equation 1.6.
This also shows elimination due to the transfer to the enzyme-product complex
or breaking down into enzyme and drug with by-products through equation 1.7.
Figure 6.15: Plot showing the Enzyme-Product complex, EP, over time in the Smooth
Endoplasmic Reticulum (left) and the EP level during the first enzyme burst (right).
The initial EP levels drop during the first enzyme burst and shows no recovery
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during the time period. This is due to the need for enzyme to be present for its
creation in equation 1.9.
Figure 6.16: Plot showing the Product level curve over time in the Smooth Endo-
plasmic Reticulum (left) and the Product level during the first enzyme burst (right).
This plot shows that the Product is created at the same time as the first
enzyme burst but after a very short period the level drops. This is due to the
level being decayed by the creation rate of the enzyme-product complex since this
is a reversible equilibrium.
6.2 Discussion
In this chapter we have considered a model of a drug diffusing into a single cell
where it is acted upon by the P450 cycle that allows for more realism to be in-
cluded. The drug was successfully diffused across the cell wall boundary and then
proceeded to be either metabolised within the Smooth Endoplasmic Reticulum
or built up in the Nucleus.
At the end of the simulation the shape of the cell was like a bucket since the low-
est drug level was in the SER and highest in the drug reservoir around the cell.
The associated integration curve showed an absorption period, which represents
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the time taken to get from the outside region across the cell wall and into the
cytoplasm.
During the only enzyme peak the drug shows an absorption period followed by
elimination/complex creation. After this time the drug level shows a levelling
until the enzyme can return to a high enough level for more metabolism.
Both the enzyme and enzyme-drug complex level show a very quick drop in level
within the first hour of simulation and shows no recovery during the time period.
The ES complex level reduction is due to irreversible transition to the FS that
peaks at the same time as the ES dips. The FS is then steadily oxygenated into
FSO2, which in turn is irreversibly changed to GSO2.
Both the GSO2 and HSO level are eliminated within the SER due to breaking
down into by-products and enzyme-product complex creation in the HSO case.
This plot shows that the Product is created at the same time as the first enzyme
burst but after a very short period the level drops. This is due to the level be-
ing decayed by the creation rate of the enzyme-product complex since this is a
reversible equilibrium.
This simulation has shown how spatial effects need to be included in order to
become more realistic. The other point of this simulation was to look at the dy-
namics at a finer scale and it seems that the dynamics are similar to the cellular
automata in so far as the drug level within the SER drops very quickly. The drug
level is accumulated in the nucleus and if there was a killing protocol within the
COMSOL program the cell would be dead very early on as the peak is 0.25 which
is much greater than the cellular automata‘s 0.00001 active threshold.
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Chapter 7
Conclusions and Further Work
7.1 Aims
The main aim of this thesis was to investigate Cytochrome P450 enzymes and
their effect on drug metabolism.
Initially this was through the use of the Hepatic Reductase Null (HRN) mice
in comparison to their wild type counterparts shown in Chapter 3. This was
done through using a number of different compartmental models and compared
with drug data provided by CXR Biosciences. The main focus of this modelling
was whether there were metabolic differences that were produced as a side ef-
fect of genetic mutation in the transgenic mouse. A three compartment model
was developed through adding time dependent excretion and a compartment that
represented the fat cells in the liver that may change the dynamics of lipophilic
drugs.
After this solely deterministic approach in conjunction with experimental data
a cellular automaton was then developed in Chapter 5 to analyse how the Cy-
tochrome P450 enzymes affect drug metabolism in general. The results were not
compared to the data used in Chapter 3 as the aim was to get an indication of
how the CYP enzymes would affect drug dynamics in a tumour.
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In Chapter 6 a COMSOL simulation was performed on a singular cell to see
whether spatial effects such as the fact that P450 enzymes are mostly found in
Smooth Endoplasmic Reticulum on the cellular level would affect the drug dy-
namics.
7.2 Compartment Models
The compartment models developed in chapter 3 show the variability in drug
metabolism between the wild type and transgenic (HRN) mouse. The problem
with fitting the compartment models to these sets of data is generated by exper-
imental constraints. It would be easier if more data were available instead of just
three mice of each type for each drug. This would mean that the average would
be statistically more representative which would aid in providing a better fit.
Other than the number of mice it would be useful if more samples could be taken
or at least they could be more regular. However this is unfeasible since the vol-
ume of blood in a mouse is finite and takes a while to replenish. It is due to these
constraints that sampling is prioritised within the first hour after the dose. For
some of the drugs shown in this chapter earlier sampling is needed in order to
record concentrations during fast processes such as absorption e.g. Caffeine.
A table summarising the success in fitting the models to the CXR Bioscience
data:
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Drug Wild Type Hepatic Reductase Null
Caffeine, Dextromethorphan 1 2
Tamoxifen 2 2
Thalidomide 2 3
Gefitinib, Omeprazole
3 2
Paclitaxel
Diclofenac, Imatinib
3 3
Midazolam
Table 7.1: Summary of Compartmental Models chosen for each CXR Bioscience Ex-
periment.
Since all three models developed were fitted using the non-linear least squares
in R the results are comparable. From the table above it is visible that all three
models were used to fit the wild type mice whereas just models 2 and 3 were used
for the transgenic mouse.
This area of modelling is useful since the curves generated are able to mimic real
life. The only drawback to the work shown in Chapter 3 was that even though
the models emulated some of the drug behaviour but sometimes more complexity
was needed in order to fully explain the mechanism of action in the wild type and
HRN mice. If it was possible to fully explain the action of the drug for both types
of mouse it would be easier to show the specific metabolic differences between
the transgenic and wild type. From the work presented it can be seen that the
HRN mouse has a slower metabolism than the wild type and with respect to the
Tamoxifen models the liver is physiologically different.
7.3 Sensitivity Analysis
The sensitivity analysis for the models shown in Chapter 4 was useful to see which
are the powerful parameters for each system in order to check for robustness to
errors in estimation. The analysis from this method is less clear as the models get
more complex. For example model 1 only has one parameter so it is very clear
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that this affects the model more than anything else whereas for the Cytochrome
P450 cycle and model this is very unclear. In these two models the parameters
affecting one variable are carried over to other connected variables.
The techniques for finding the sensitive parameters outlined in this chapter are
easily applied and return good results so long as the model is simple enough.
It is possible that the difference taken of 10% in the parameters is too small to
gain insight into the larger models. When the magnitude test was unclear it was
useful to have the extended sensitivity analysis plots or ranges to illuminate the
power of each parameter this was particularly useful for the larger models.
7.4 Multiscale Cellular Automaton
In chapter 5 a multiscale model was developed that models a growing solid tu-
mour that combines the cell cycle, the Cytochrome P450 enzymatic cycle with
drug diffusion. The model incorporates spatial and deterministic models allowing
for a more realistic approach to death through drug level and growth of cancer
cells. As such it is possible to analyse dosing strategy whether it be level or
location.
The different regimens have shown a number of aspects of the model’s applicabil-
ity. The side and central dosing regimes results differ due to proximity of tumour
tissue to the dose squares. The constant side infusion works well to kill the tu-
mour but is not feasible since it is not possible to set up in real life. In real life
chemotherapy the dosing strategy tries to limit the amount of systemic damage
caused by the cytotoxic drugs. This is done by locating the tumour and injecting
as close as possible, which would be analogous to the central dose if close and the
side dose if the drug has to diffuse towards the tumour.
The oxygen level affects both the cell and P450 cycle, which in turn affects tumour
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growth. In the cell cycle this is controlled by the variation in the µ parameter
which can be affected by lack of space within the tumour this is what can cause
the generation of the necrotic core. The oxygen component in the P450 cycle
affects the product level but not the drug itself. This means that if the program
was used for a prodrug where the [P] level is important the oxygen level would
also matter.
The Cytochrome P450 model is a useful application since it delays the drug level
change but the parameters need adjusting since it does not rise high enough to
kill many tumour cells.
The drug diffusion, dose and decay are currently arbitrary and therefore not re-
lated to any drug in particular. It is intended to make this more realistic by
relating these parameters to known properties of actual drugs using half lives ob-
tained through in vitro and in vivo diffusion experiments. Diffusion coefficients
are related to both the size of the molecule and the functional groups. It is diffi-
cult to estimate this coefficient since these two properties vary between chemicals.
Diffusion experiments with agar are difficult to compare with different tissue me-
dia. Functional group specificity can cause issues in prediction since it can mean
the drug reacts in the wrong part of the organism.
This program is applicable to other areas other than the one stated here. For
example any area that deals with interactions between tissue media and drugs
like in toxicology and drug studies. The cell cycle inside the code deals with
tumour cells but this code can be re-parameterised to concentrate on other types
of cell including normal cells, hepatic tissue etc.
As such it could be used as part of a multi-system approach to drug metabolism
if the action of the drug is roughly known. Other enzymatic systems can be used
instead of or as well as CYP e.g. UDP glycosyltransferases (UGTs). This would
allow for greater flexibility in substrate use as many drugs use multiple enzyme
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systems for their metabolism.
7.5 Drug Uptake in a Single Cell
The model of a drug diffusing into a single cell where it is acted upon by the
P450 cycle created a more realistic view of the inner metabolism of a cell. The
drug was successfully diffused across the cell wall boundary and then proceeded
to be either metabolised within the Smooth Endoplasmic Reticulum or built up
in the Nucleus.
This is interesting since it is what would be expected of a cell surrounded by a
drug reservoir i.e. that the drug would diffuse in and then have to pass through
the internal cell structures at a slower rate to reach the nucleus.
This simulation has shown how spatial effects need to be included in order to
become more realistic. The other point of this simulation was to look at the
dynamics at a finer scale and it seems that the dynamics are similar to the
cellular automata in so far as the drug level within the SER drops very quickly.
The drug level is accumulated in the nucleus and if there was a killing protocol
within the COMSOL program the cell would be dead very early on as the peak
is 0.25, which is much greater than the 0.00001 active threshold.
In the future more cell structures could be added e.g. the rough endoplasmic
reticulum, the mitochondrion and Golgi apparatus. Although Cytochrome P450
enzymes have not been discovered within them it would give an idea of the time
it would take to diffuse through them since the tissue media may differ within
them.
The other extension to this model is that the basic cell could be of a different
type e.g. hepatocyte, Kupffer or tumour cell.
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7.6 Future Work
In silico modelling approaches are useful since they can minimise experimental
costs and once set up can be used to replace animal testing for drugs. As such
modelling techniques need to be developed to reduce dependence on animals for
validation of pharmacological efficacy. The work within this thesis shows that
computational methods can be used to model biological and medical problems
effectively,
The compartment models were able to analyse the difference between the normal
and the transgenic mouse with an impaired hepatic Cytochrome P450 system. It
was possible from these models to see that metabolism of the drugs was reduced
in the HRN mouse. For some of the drugs the models need improving by the ad-
dition of more compartments or the use of more physiologically based approaches.
This is due to the fact that it is unclear in the current models where the area of
disposition for the drug is.
The spatial models outlined in this project (Multiscale Cellular Automaton and
Diffusion into a Single Cell) have added a useful dimension to this area of re-
search. The cell cycle model included in the Cellular Automaton model is a
six-component model. This could be changed to a more complex model like the
13 component model as described in Csika´sz-Nagy et al. (2006) or a more com-
plex method of nutrient heterogeneity as shown in Frieboes et al. (2009). As well
as the cell cycle the Cytochrome P450 cycle could be changed as it currently only
relates to one strain CYP1A2. This could just mean a change in the parameter
set rather than the model equations but it depends on the substrate specificity
of the strain. Another way of changing the CYP dynamics is to include a mecha-
nism for multiple strains interacting within the metabolism, which has not been
included in this project.
The inclusion of spatial effects to the deterministic models like the Cytochrome
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P450 cycle allows for greater realism in predictions of drug passage through the
body or across certain tissue media.
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